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Abstract
Terminal differentiation opposes proliferation in the vast majority of tissue types. As a result, loss of lineage
differentiation is a hallmark of aggressive cancers, including soft tissue sarcomas (STS). Consistent with these
observations, undifferentiated pleomorphic sarcoma (UPS), an STS subtype devoid of lineage markers, is
among the most aggressive and lethal sarcomas in adults. Though tissue-specific features are lost in these
mesenchymal tumors they are most commonly diagnosed in skeletal muscle and are thought to develop from
transformed muscle progenitor cells. We have found that a combination of HDAC (Vorinostat) and BET
bromodomain ( JQ1) inhibition partially restores differentiation to skeletal muscle UPS cells and tissues,
enforcing a myoblast-like identity. Importantly, differentiation is contingent upon downregulation of the
Hippo pathway transcriptional effector, Yes-activated protein 1 (YAP1) and its downstream effectors in the
NF-κB pathway. YAP1 and NF-κB are critical mediators of myoblast proliferation and their activity must be
down regulated to permit differentiation. Previously, we observed that Vorinostat/JQ1 suppresses YAP1 and
NF-κB activity and as a result, inhibits tumorigenesis, and promotes differentiation. Here I show that YAP1
and NF-B activity suppress circadian clock function, inhibiting differentiation and promoting unchecked
proliferation. In most tissues clock activation is antagonized by the unfolded protein response (UPR).
However, skeletal muscle differentiation requires both Clock and UPR, suggesting the molecular link between
them is unique in muscle. In skeletal muscle-derived UPS we observed that YAP1 suppresses PERK and
ATF6-mediated UPR target expression as well as clock genes. These pathways govern metabolic processes
including autophagy and their disruption supports a shift in metabolism toward cancer cell-associated
glycolysis and hyper-proliferation. Treatment with Vorinostat/JQ1 successfully inhibited glycolysis/MTOR
signaling, activated the clock, and upregulated the UPR and autophagy via YAP1. These findings support the
use of epigenetic modulators to treat human UPS and define the connection between these pathways and
their effects on tissue differentiation. Additionally, we identify specific metabolic and differentiation genes as
potential biomarkers of treatment efficacy.
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ABSTRACT 
 
DEREGULATION OF THE HIPPO PATHWAY SUPPRESSES DIFFERENTIATION AND 
PROMOTES SARCOMAGENESIS 
Adrian Rivera Reyes 
T.S. Karin Eisinger, Ph.D. 
 
Terminal differentiation opposes proliferation in the vast majority of tissue types. As a result, loss 
of lineage differentiation is a hallmark of aggressive cancers, including soft tissue sarcomas 
(STS). Consistent with these observations, undifferentiated pleomorphic sarcoma (UPS), an STS 
subtype devoid of lineage markers, is among the most aggressive and lethal sarcomas in adults. 
Though tissue-specific features are lost in these mesenchymal tumors they are most commonly 
diagnosed in skeletal muscle and are thought to develop from transformed muscle progenitor 
cells. We have found that a combination of HDAC (Vorinostat) and BET bromodomain (JQ1) 
inhibition partially restores differentiation to skeletal muscle UPS cells and tissues, enforcing a 
myoblast-like identity. Importantly, differentiation is contingent upon downregulation of the Hippo 
pathway transcriptional effector, Yes-activated protein 1 (YAP1) and its downstream effectors in 
the NF-κB pathway. YAP1 and NF-κB are critical mediators of myoblast proliferation and their 
activity must be down regulated to permit differentiation. Previously, we observed that 
Vorinostat/JQ1 suppresses YAP1 and NF-κB activity and as a result, inhibits tumorigenesis, and 
promotes differentiation. Here I show that YAP1 and NF-kB activity suppress circadian clock 
function, inhibiting differentiation and promoting unchecked proliferation. In most tissues clock 
activation is antagonized by the unfolded protein response (UPR). However, skeletal muscle 
differentiation requires both Clock and UPR, suggesting the molecular link between them is 
unique in muscle. In skeletal muscle-derived UPS we observed that YAP1 suppresses PERK and 
ATF6-mediated UPR target expression as well as clock genes. These pathways govern metabolic 
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processes including autophagy and their disruption supports a shift in metabolism toward cancer 
cell-associated glycolysis and hyper-proliferation. Treatment with Vorinostat/JQ1 successfully 
inhibited glycolysis/MTOR signaling, activated the clock, and upregulated the UPR and 
autophagy via YAP1. These findings support the use of epigenetic modulators to treat human 
UPS and define the connection between these pathways and their effects on tissue 
differentiation. Additionally, we identify specific metabolic and differentiation genes as potential 
biomarkers of treatment efficacy. 
 
  
 
ix 
TABLE OF CONTENTS 
 
DEDICATORIA/DEDICATION………………………………………………………..iii 
ABSTRACT……………………………………………………………………………...1 
LIST OF ILLUSTRATIONS…………………………………………………………….6 
CHAPTER 1: INTRODUCTION……………………………………………………….7 
Soft Tissue Sarcoma (STS) Overview…………………………………………………………………7 
Undifferentiated Pleomorphic Sarcoma (UPS): an STS Subtype…………………….................8 
Skeletal Myogenesis and Differentiation …………………………………………………………...10 
Hippo Signaling Pathway and Muscle Differentiation ……………………………………………12 
NF-kB Signaling Pathway and Muscle Differentiation…………………………………...............15 
Circadian Clock and Muscle Differentiation ……………………………………………………….20 
Endoplasmic Reticulum (ER) Stress, the Unfolded Protein Response (UPR), and Muscle 
Differentiation…………………………………………………………………………………………….23 
Autophagy and Muscle Differentiation.……………………………………………………………..27 
Summary ………………………………………………………………………………………...............30 
CHAPTER 2: MATERIALS AND METHODS ……………………………………..31 
Genetically Engineered Mouse Models (GEMM) ………………………………………………….31 
In vivo drug treatment ………………………………………………………………..………………..31 
Oncomine and TCGA survival analysis …………………………………………………………….31 
Cell Lines …………………………………………………………………………………………………32 
Drug Treatments ………………………………………………………………………………………..32 
Lentiviral Transduction ………………………………………………………………………………..32 
  
    x   
ChIP-seq ………………………………………………………………………………………………….33 
Transient Transfections ……………………………………………………………………………….33 
UPR Reporter Assays ………………………………………………………………………………….33 
Immunoblots …………………………………………………………………………………………….33 
qRT-PCR ………………………………………………………………………………………………….34 
Luciferase assay ………………………………………………………………………………………..34 
Microarray and gene set enrichment analysis …………………………………………………….34 
Accession Codes ……………………………………………………………………………………….35 
C2C12 growth and differentiation ……………………………………………………………………36 
Immunohistochemistry ………………………………………………………………………………..36 
GC/MS …………………………………………………………………………………………………….37 
Statistical Analysis ……………………………………………………………………………………..38 
CHAPTER 3: YAP1 ENHANCES NF-kB-DEPENDENT AND INDEPENDENT 
EFFECTS ON CLOCK-MEDIATED UNFOLDED PROTEIN RESPONSE AND 
AUTOPHAGY IN SARCOMA………………………………………………………..39 
Introduction ……………………………………………………………………………………………...39 
Results ……………………………………………………………………………………………………42 
 Clock gene expression is high in differentiating muscle and lost in UPS …………..........42 
 YAP1 suppresses circadian clock gene expression in UPS ……………………………….47 
 Circadian clock genes are regulated by NF-kB downstream of YAP1 ……………….......51 
 YAP1/NF-kB loss initiates a muscle differentiation-associated UPR response ………….55 
 SAHA/JQ1 treatment promotes oscillation of UPR target genes ………………………….59 
 Pharmacological and genetic inhibition of YAP1 alters sarcoma cell metabolism ...........62 
 YAP1, but not NF-kB, suppresses autophagy in UPS cells ………………………………..66 
 
Discussion ……………………………………………………………………………………………….71 
CHAPTER 4: CONCLUSION ………………………………………………………..74 
  
    xi   
Future Directions ……………………………………………………………………………………….76 
YAP1 as a transcriptional repressor………………………………………………………..…76 
Mouse Models and Pharmacological Approaches………………………………………..…77 
Future potential treatments for sarcoma…………………………………………………...…78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    xii   
List of Illustrations 
Figure 1: Hippo signaling pathway 
Figure 2: Canonical (left) and non-canonical (right) NF-kB pathways 
Figure 3: Circadian clock signaling 
Figure 4: Unfolded protein response (UPR) signaling pathways  
Figure 5: Autophagy model  
Figure 6: Yap1-dependent inhibition of circadian clock genes in UPS and proliferating myoblasts 
Figure 7: Clock genes in human UPS tumors  
Figure 8: Yap suppresses clock gene expression 
Figure 9: Yap-mediated suppression of the clock enhances sarcoma proliferation 
Figure 10: Inhibition of NF-kB, downstream of Yap1, restores clock gene expression 
Figure 11: Inhibition of YAP1 and NF-kB activates UPR target gene expression 
Figure 12: Txnip and Ddit3 are necessary for survival during muscle differentiation 
Figure 13: SAHA/JQ1 treatment promotes UPR target oscillation 
Figure 14: SAHA/JQ1 treatment induces the PERK and ATF6 arms of the UPR.  
Figure 15: YAP1 loss alters sarcoma cell metabolism and initiates differentiation 
Figure 16: YAP1 suppresses autophagy in sarcoma cells independent of NF-kB 
Figure 17: Model of YAP1/NF-κB-mediated clock control of UPR and NF-κB-independent control 
of autophagy 
  
    1   
Chapter 1: Introduction 
 
Soft Tissue Sarcoma (STS) Overview 
Nearly 200,000 people worldwide and 12,000 Americans are diagnosed with soft-tissue 
sarcoma (STS) with approximately 4,000 deaths every year in the United States (Taylor et al. 
2011; Siegel et al. 2018). This complex set of tumors arises in mesenchymal tissues such as 
connective, adipose tissue, and skeletal muscle tissues (Jo & Fletcher 2014). STS are rare adult 
tumors that account for less than 1% of all adult malignancies (Siegel et al. 2018). The roughly 65 
known sarcoma subtypes can be very generally divided into two groups 1) majority pediatric 
sarcomas which most frequently develop as a result of chromosomal translocations and have 
near diploid karyotypes (Borden et al. 2003; Mertens et al. 2009; Kadoch & Crabtree 2013; 
Ciarapica et al. 2014; Shern et al. 2014) and 2) adult sarcomas that have no known consistent 
oncogenic mutations, but ~50% of which bear mutations in tumor suppressor genes like RB1 or 
p53, often referred to as genetically and karyotypically complex (Borden et al. 2003; Mertens et 
al. 2010; W. Lee et al. 2014; De Raedt et al. 2014; M. Zhang et al. 2014). Due to their karyotype 
complexity, variety of subtypes, and the lack of known drivers, adult sarcomas are poorly 
understood. Thus, treatment options are generally limited to radiation and surgery, as inadequate 
characterization has precluded the development of targeted therapies (Taylor et al. 2011; Pappo 
et al. 2014; Wagner et al. 2015). 
 
Sarcomas with simple genetic alterations generally arise because of gene translocations. In 
some cases, there is only one defining genetic abnormality present during tumor initiation 
(Mertens et al. 2009). These tumors with near diploid karyotypes account for one third of all 
sarcomas (Mertens et al. 2009). In contrast, genetically and karyotypically complex sarcomas can 
develop slowly and accumulate mutations or aberrations that lead to genetic complexity 
throughout time (Horvai et al. 2009; Rosai et al. 1996; Snyder et al. 2009). Most high-grade 
karyotypically complex sarcomas arise spontaneously and without previous lower-grade lesions 
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(Helman & Meltzer 2003; Clark et al. 2005; Mertens et al. 2010). These tumors are poorly 
understood due to their complexity, variety of subtype, and lack of known drivers. Current 
treatment options are limited to radiation and surgery, because development of targeted therapies 
has lagged due to inadequate characterization of STS (Pappo et al. 2014; Wagner et al. 2015; 
Taylor et al. 2011). Our current work focuses on an aggressive adult tumor found in skeletal 
muscle, undifferentiated pleomorphic sarcoma (UPS). 
 
Undifferentiated Pleomorphic Sarcoma (UPS): an STS Subtype 
Undifferentiated pleomorphic sarcoma (UPS) is one of the most common and frequently 
diagnosed adult STS subtypes (Jo & Fletcher 2014). Because UPS’s etiology is unknown, it is a 
diagnosis of exclusion (Lawrence et al. 1987; Jo & Fletcher 2014). UPS tumors are characterized 
by cytogenetic abnormalities such as chromosomal deletions, amplifications, chromosomal gains 
and losses, and aneuploidy (Albertson et al. 2003). These high-grade tumors do not seem to 
present consistent genetic aberrations or chromosomal abnormalities, which makes it difficult to 
identify the contributions of any genetic abnormality in these tumors (Mertens et al. 2002). 
Although UPS can be found in various tissues, it is most commonly found in skeletal muscle 
(Ballinger et al. 2016). 
 
Currently, there are two models regarding the etiology of UPS. The first model suggests 
that UPS represents not just a single sarcoma subtype, but a number of phenotypes that are 
common to other sarcomas in advanced stages (Matushansky et al. 2009). In this model, the 
common idea is that tumors de-differentiate as they progress, resulting in a high-grade UPS 
(Matushansky et al. 2009; Murphey 2007). The second model suggests that UPS tumors result 
from the transformation of mesenchymal stem cells (Matushansky et al. 2009; Murphey 2007). In 
this model, it is thought that muscle progenitor cells, or satellite cells, give rise to skeletal muscle-
derived UPS (Rubin et al. 2011).  
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UPS tumors can arise in any part of the body, but they most often develop in extremities 
and torso (Lawrence et al. 1987; Pitcher et al. 1994; Zornig et al. 1992). The majority of UPS 
tumors present themselves as painless masses throughout the body and grow locally (Jo & 
Fletcher 2014). These tumors are associated with poor clinical outcome, as they frequently enter 
the bloodstream and metastasize to the lungs (Christie-Large et al. 2008; Matushansky et al. 
2009). Thus, understanding the cellular and molecular mechanisms that direct and control UPS 
metastasis is an important and prominent field of research. The tumor microenvironment in UPS 
has been shown to be dependent on lack of oxygen or hypoxia (Eisinger-Mathason et al. 2013). 
 
Due to its metastatic capacity and lack of targeted therapies, UPS is particularly hard to 
treat (Ballinger et al. 2016). Targeted therapies for UPS have proven difficult because of the lack 
of evidence and knowledge regarding the molecular mechanisms that drive these tumors (Taylor 
et al. 2011; Kelleher & Viterbo 2013). Among the treatments that exist for UPS patients are 
surgery, radiation, and chemotherapy (Taylor et al. 2011). The most effective treatment includes 
radical surgeries, in which the tumor, blood vessels and lymph nodes are removed (Linehan et al. 
2000). Conversely, as radical surgeries are not always an option for patients, more conservative 
surgeries are performed, which can often lead to tumor recurrence. In order to improve patient 
outcome, prognosis and quality of life, these conservative surgeries could be combined with 
targeted therapies that inhibit cell proliferation or metastasis potential. 
 
In order to develop new treatments or targeted therapies for UPS, it is essential to 
develop accurate models. A common model used to understand UPS tumors is the LSL KrasG12D; 
Trp53-/- (KP) mouse model. This model of UPS skeletal muscle UPS relies simultaneous Cre-
dependent expression which is injected into the right gastrocnemius muscle of mice in order to 
activate oncogenic Kras and delete the p53 gene (Kirsch et al. 2007). Tumors arise 
approximately 45 days post-intramuscular injection of adenovirus expressing Cre recombinase. 
Although human sarcomas do not frequently express mutated KRAS, KP sarcomas of 
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gastrocnemius muscle recapitulate human UPS with regard to transcriptional profiles, histology, 
morphology, and metastatic capacity (Mito et al. 2009). Importantly, roughly 50% of human 
sarcomas possess Trp53 mutations, suggesting that loss of p53 function combined with hyper-
proliferation induced errors will initiate UPS (Guijarro et al. 2013). This hypothesis is supported by 
additional models in which KRAS mutation can be replaced by intramuscular cardiotoxin injection 
and still develop UPS tumors (Van Mater et al. 2015). Moreover, the tumors that develop from the 
KP model are driven by hypoxia and HIF1a to metastasize to the lung, as does human UPS 
(Eisinger-Mathason et al. 2013). Additionally, within weeks of injection, subcutaneous allografts of 
murine UPS cells will also metastasize to the lung (Eisinger-Mathason et al. 2013). This murine 
model along with in vitro and human UPS tumor sections allow for the investigation of molecular 
mechanisms that promote primary UPS formation and metastasis. 
 
Skeletal Muscle Myogenesis and Differentiation 
As mentioned earlier, one hypothesis for UPS tumor formation suggests that these tumors 
result from the transformation of mesenchymal stem cells, or skeletal muscle progenitor cells 
(Matushansky et al. 2009; Murphey 2007; Rubin et al. 2011). Skeletal muscle myogenesis is a 
complex process that commences during embryonal development and by which muscle tissues 
are formed (Parker et al. 2003; Sambasivan & Tajbakhsh 2007). During embryonic development, 
mesenchymal stem cells give rise to muscle fibers. Next, mesenchymal stem cells give rise to 
muscle fibers that fuse with myoblasts to form multinucleated myotubes (Parker et al. 2003; 
Sambasivan & Tajbakhsh 2007). Muscle progenitor cells then enter a quiescent state and reside 
as satellite cells (Schultz 1996; Davis & Fiorotto 2009). To maintain tissue homeostasis, skeletal 
muscle tissue relies on satellite cells that can self-renew muscle tissue by differentiating into new 
fibers (Schmalbruch & Lewis 2000; Pellettieri & Sánchez Alvarado 2007; Chargé & Rudnicki 
2004). Thus, it is hypothesized that deregulation of satellite cell differentiation contributes to UPS 
formation.  
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Conversely, myogenesis is regulated by cell surface receptors that activate intracellular 
signal transduction pathways (Kuang et al. 2008; Bentzinger et al. 2010). These signaling 
molecules promote transcription of genes and microRNAs that allows precursor cells to commit to 
the myogenic lineage and develop into muscle (He et al. 2009). In the embryo, the first skeletal 
muscle cells that form are myocytes (Lyons, Buckingham, et al. 1991; Lyons, Mühlebach, et al. 
1991; Chal et al. 2018). These newly formed myocytes further differentiate via Wnt11 expression 
and signaling, which allows for their elongation along the anterior-posterior axis (Denetclaw et al. 
1997; Gros et al. 2009). Next, the myocytes mature into the myotome once they express MyoD 
and Myf5 (Sassoon et al. 1988; Kiefer & Hauschka 2001). Once both MyoD and Myf5 are 
expressed, the myocytes commit to the muscle lineage and develop into muscle (Pownall et al. 
2002). MYOD is a powerful and tightly regulated muscle transcription factor, which along with 
myocyte enhancer factors (MEFs) drive a muscle differentiation transcriptional program (Pownall 
et al. 2002; Conerly et al. 2016). Moreover, there is evidence demonstrating that the Hippo 
signaling pathway modulates myogenesis and muscle regeneration, as well as inhibit embryonic 
stem cell differentiation (Fischer et al. 2016; Lian et al. 2010). 
 
Hippo Signaling Pathway and Muscle Differentiation 
The Hippo signaling pathway is an evolutionary conserved network first discovered and 
characterized in Drosophila melanogaster and is the master regulator of organ size control, cell 
proliferation, cell fate, stem cell self-renewal, and tumorigenesis (Misra & Irvine 2018; Staley & 
Irvine 2012; Ramos & Camargo 2012). The Hippo signaling pathway is a kinase cascade that 
responds to various external stimuli and key regulators (Hamaratoglu et al. 2006; Yu & Guan 
2013). The pathway consists of the mammalian kinases MST1/2 and LATS1/2, the effector 
protein Yes-activated protein (YAP1) and the transcriptional co-activator with PDZ binding motif 
(TAZ) (Yu & Guan 2013; Callus et al. 2006; Barron & Kagey 2014). For the purpose of this 
dissertation, I will focus solely on YAP1 and not TAZ. The MST1/2 kinases directly phosphorylate 
LATS1/2 and the protein SAV1 facilitates the interaction between both sets of proteins and 
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allowing for phosphorylation to occur (Yu & Guan 2013; Callus et al. 2006). In order to bind the 
DNA and drive the Hippo transcriptional program, YAP1 must form a heterodimer with the Tea 
Domain Family transcription factor (TEAD). The TEAD proteins contain a canonical M-CAT motif 
(5’-TCATTCCT-3’) that is often found in the promoters of muscle associated genes (Larkin et al. 
1996; Jiang et al. 2000). YAP1-TEAD complexes bind the M-CAT motif to drive or inhibit 
transcription of genes (Ye et al. 2018; Eisinger-Mathason et al. 2015; Liu-Chittenden et al. 2012; 
Zhao et al. 2007; Barron & Kagey 2014).  
 
In order for YAP1 to translocate into the nucleus, bind TEAD, and promote its transcriptional 
program, YAP1 must remain unphosphorylated (Ren et al. 2010). The LATS1/2 kinases mediate 
YAP1 phosphorylation (Zhao et al. 2007). Phosphorylation of the YAP1 hinders its ability to 
translocate into the nucleus and is thus sequestered via 14-3-3 binding and degraded in the 
cytoplasm (Zhao et al. 2007) (Figure 1). As a transcriptional modulator, YAP1 is able to regulate 
expression of genes that are involved in tumor cell proliferation, epithelial to mesenchymal 
transition, invasion and metastasis (Zhao et al. 2007; Eisinger-Mathason et al. 2015; Mizuno et al. 
2012; Yang et al. 2015; Muramatsu et al. 2011). 
 
The Hippo pathway plays an important role in modulating myogenesis and muscle 
regeneration, and also inhibits embryonic stem cell differentiation (Fischer et al. 2016; Lian et al. 
2010). During skeletal muscle myogenesis, activated satellite cells expand and differentiate, 
whereas quiescent satellite cells localize between the basal lamina and plasma membrane of 
myofibers (M. Zhang & McLennan 1999; Lepper & Fan 2010). In satellite cell-derived myoblasts, 
it has been shown that YAP1 knockdown does not affect differentiation but reduces proliferation 
(Nagata et al. 2006). There is evidence showing that YAP1 activity inhibits skeletal muscle 
differentiation, as YAP1 overexpression leads to inhibition of MYOD expression (Gee et al. 2011; 
Watt et al. 2015). Moreover, in vitro overexpression of constitutively active YAP1 in myoblast 
precursors inhibits differentiation by altering the transcriptional program (Ishibashi et al. 2005; De 
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Falco & De Luca 2006; Watt et al. 2010). In terms of YAP1 regulation, it has been demonstrated 
that caspase 3 activates the Hippo kinase, MST1, during myoblast differentiation (Fernando et al. 
2002).  
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Figure 1: Hippo signaling pathway 
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Last, deregulation of YAP has been observed in epithelial tumors such as breast and liver 
cancer, among others, as well as mesenchymal tumors, such as soft tissue sarcoma (Eisinger-
Mathason et al. 2015; Muramatsu et al. 2011; Z. Wang et al. 2014; M. Z. Xu et al. 2009; M. Song 
et al. 2012; Ahmed et al. 2015; Mohamed et al. 2015). Research from our lab has shown that the 
Hippo signaling pathway is silenced in UPS, which allows for uncontrolled activation of YAP1 
(Eisinger-Mathason et al. 2015; Mizuno et al. 2012). YAP1 is also stabilized in human UPS 
tumors and promotes a pro-proliferation transcriptional program (Eisinger-Mathason et al. 2015; 
Mizuno et al. 2012). YAP1 stabilization in these tumors and other sarcomas is due to Hippo 
pathway kinase deletion and epigenetic silencing of its inhibitor, Angiomotin (AM(Ye & Eisinger-
Mathason 2016). These perturbations stabilize YAP1 at the protein level and enhance its 
transcriptional activity by increasing its nuclear localization (Ye & Eisinger-Mathason 2016).  Our 
work has also shown that elevated YAP1 levels result in heightened NF-kB signaling in UPS (Ye 
& Eisinger-Mathason 2016). Interestingly, in myoblasts, it has been shown that NF-kB signaling 
downregulates MYOD expression in myoblast seem to be mutually exclusive (Guttridge et al. 
2000). Though well studied in epithelial tumors, the specific downstream effectors of YAP1 in 
sarcomas are still being elucidated. 
 
NF-kB Signaling Pathway and Muscle Differentiation 
The NF-kB signaling hub is a family of transcription factor regulators that consists of DNA 
binding proteins (Karin 2006; Perkins 2012). The NF-kB family of proteins are known to regulate 
cell proliferation, inhibit apoptosis, promote cell migration and invasion, and stimulate 
angiogenesis and metastasis (Karin & Greten 2005). NF-kB activation can be induced by viral 
and bacterial infections, necrotic cell products, DNA damage, oxidative stress, and 
proinflammatory cytokines (Karin & Greten 2005). The two pathways that comprise the NF-kB 
signaling hub are the canonical and noncanonical pathways (Karin & Greten 2005) (Figure 2). 
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The canonical pathway is activated transiently and rapidly by proinflammatory cytokines that 
interact with specific receptors or adaptor molecules (Karin & Greten 2005). 
 
The effector molecules for the canonical pathway are p50-p65 (RELA) heterodimers (Karin & 
Greten 2005; Sun 2017; Bonizzi & Karin 2004). In canonical NF-kB, the activation of the p50-p65 
dimer depends on the degradation of the NF-kB specific inhibitor IkB, which releases the dimer 
after it becomes phosphorylated by the IKK subunits, IKKa and IKKb (Karin & Greten 2005). The 
IKK subunits are necessary to activate both NF-kB pathways. The IKKa-IKKb heterodimer 
activates the canonical pathway (Karin & Greten 2005; Sun 2017; Bonizzi & Karin 2004; 
Senftleben et al. 2001). Additionally, canonical signaling requires the IKKg regulatory subunit, or 
NEMO, which holds the IKKa-IKKb heterodimer in place so that the heterodimer can trans-
autophosphorylate (Karin & Greten 2005; Karin 2006; G. Xu et al. 2011; Rothwarf & Karin 1999). 
In order for the trans phosphorylation of the IKK heterodimer to occur, the IKKg subunit must be 
polyubiquitinated in its K63 residue (Chen 2012; Tokunaga & Iwai 2012) (Figure 2, left). NF-kB 
activity is also modulated downstream by various microRNAs (miRNAs) that target mRNAs 
coding for the IKK proteins, as well as it can be modulated upstream by other protein regulators 
(X. Ma et al. 2011; Boldin & Baltimore 2012; Taganov et al. 2006).  
 
Furthermore, the noncanonical pathway activation is a slower process that requires de novo 
synthesis of NF-kB inducing kinase (NIK) (Vallabhapurapu & Karin 2009). NIK phosphorylates the 
IKKa-IKKa homodimer, which is required to activate the noncanonical pathway (Karin & Greten 
2005; Sun 2017; Bonizzi & Karin 2004; Senftleben et al. 2001). Next, the IKKa-IKKa homodimer 
phosphorylates p100, which is then polyubiquitinated and cleaved to produce p52 (Karin & 
Greten 2005; Sun 2017; Bonizzi & Karin 2004; Senftleben et al. 2001). The effector molecules for 
the noncanonical pathway are p52 and RELB, which form a heterodimer and translocate into the 
nucleus to drive or inhibit transcription of target genes (Karin & Greten 2005; Sun 2017; Bonizzi & 
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Karin 2004) (Figure 2, right). For the purpose of this dissertation, I will focus on canonical NF-kB 
signaling.  
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Figure 2: Canonical (left) and non-canonical (right) NF-kB pathways 
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NF-kB signaling activation has been associated with promoting myogenesis formation but 
also its hyperactivation has been associated with multiple skeletal muscle abnormalities such as 
a cachexia, muscular dystrophy, inflammatory myopathy and rhabodomyosarcomas, among 
others (Creus et al. 2009; Li et al. 2008; Mourkioti & Rosenthal 2008; Peterson & Guttridge 2008). 
Additionally, NF-kB transcriptional and DNA binding activity has been shown to decline over the 
course of myogenic differentiation (Egerman & Glass 2014; Catani et al. 2004; Dee et al. 2003; 
Guttridge et al. 2000). NF-kB signaling can also promote transcription of targets that repress 
myogenic differentiation, such as Cyclin D1, as well as by suppressing MyoD synthesis (Guttridge 
et al. 2000; Skapek et al. 1995; Sitcheran et al. 2003).  
 
In cancer, NF-kB is often found constitutively active, and this hyperactivation is seldom 
due to genetic alterations (Karin & Greten 2005; Staudt 2010; Ben-Neriah & Karin 2011). In solid 
tumors, increased NF-kB activity is due to elevated production of activating cytokines (Ben-
Neriah & Karin 2011; DiDonato et al. 2012). In human UPS, we have shown that NF-kB is the 
most transcriptionally active pathway (Ye et al. 2018). Additionally, we have demonstrated that 
YAP1 suppresses expression of a newly identified negative regulator of NF-kB signaling, 
Ubiquitin Specific Peptidase 31 (USP31), which predictably results in tumorigenesis and cell 
hyperproliferation (Ye et al. 2018; Tzimas et al. 2006; Lockhart et al. 2004). Additionally, we have 
established a connection between the Hippo signaling pathway effector protein, YAP1, and NF-
kB signaling, as YAP1 inhibition restored UPS31 expression (Ye et al. 2018). Our findings 
suggest that skeletal muscle-derived UPS behave similar to proliferating myoblasts, as these 
tumors are not able to undergo differentiation due to persistent YAP1 and NF-kB activation. 
Interestingly, we and others have observed NF-kB signaling oscillation over time in skeletal 
muscle precursor cells as well as other tissues (Ye et al. 2018; Zambrano et al. 2016; X. Wang et 
al. 2015) (Ye et al., 2018; Zambrano et al., 2016; Wang et al., 2015). The oscillatory pattern 
exhibited by NF-kB signaling is reminiscent of circadian clock oscillation, which is known to 
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regulate NF-kB signaling and has been linked to muscle differentiation and normal myoblast 
proliferation (X. Wang et al. 2015; Andrews et al. 2010; McCarthy et al. 2007; X. Zhang et al. 
2009). 
 
Circadian Clock and Muscle Differentiation 
The circadian clock is a 24-hour intrinsic molecular signaling network that synchronizes 
physiology and behavior and is known to regulate cellular metabolism (Lowrey & Takahashi 2004; 
Bass & Takahashi 2010; Altman et al. 2015). The clock is regulated by a network of positive and 
negative feedback loops that drive rhythmic expression of genes over a 24-hour period (Bell-
Pedersen et al. 2005). The clock also regulates proliferation by controlling a diverse array of 
metabolic processes (Lowrey & Takahashi 2004; Bass & Takahashi 2010; Huang et al. 2016). 
The clock can also be influenced by environmental changes which in turn can affect gene 
expression and behavior (Lowrey & Takahashi 2004). 
 
The main clock transcriptional proteins are CLOCK and BMAL1, which heterodimerize in the 
nucleus to promote transcription of clock target genes by binding to the E-box in the promoters of 
such genes (Lowrey & Takahashi 2004; Ripperger & Schibler 2006). The CLOCK-BMAL1 
heterodimer promotes transcription of PERIOD (PER) and CRYPTOCHROME (CRY) genes, 
which are part of negative feedback loop that inhibits the CLOCK-BMAL1 heterodimer (Lowrey & 
Takahashi 2004; Ripperger & Schibler 2006). Once PER and CRY are expressed, they shuttle to 
the cytoplasm where they form a multimeric complex with casein kinase 1e and translocate into 
the nucleus to inhibit the CLOCK-BMAL1 heterodimer and shut off circadian clock activity (Eide et 
al. 2005; Kume et al. 1999; C. Lee et al. 2001; Sangoram et al. 1998; Lowrey & Takahashi 2004; 
Ripperger & Schibler 2006). Importantly, PER is responsible for regulating and coordinating the 
entry of the complex into the nucleus (C. Lee et al. 2001). On the other hand, CRY is responsible 
for inhibiting the histone acetyltransferase p300, which decreases CLOCK-BMAL1-mediated 
transcription (Etchegaray et al. 2003) (Figure 3). This PER-CRY-mediated feedback loop coupled 
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with the CLOCK-BMAL1-mediated feedforward loop give the clock the oscillatory pattern that 
characterizes it. 
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Figure 3: Circadian clock signaling 
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Circadian clock function has been shown to be necessary for muscle generation and 
differentiation, especially because MyoD is a transcriptional target of the clock (Andrews et al. 
2010; X. Zhang et al. 2012; Lefta et al. 2011). Similar to NF-kB deficient mice, clock deficient 
mice have altered metabolism and develop muscle weakness and cachexia (Bohnert et al. 2016). 
Moreover, the clock has been shown to control NF-kB through induction of CLOCK (Spengler et 
al. 2012). Although there is some evidence showing a molecular connection between the clock 
and NF-kB signaling, the dynamics of how both signaling hubs regulate each other remain to be 
elucidated.  
 
Recent studies have also shown that there is a molecular connection between the circadian 
clock and other pathways associated with muscle differentiation, such as the Unfolded Protein 
Response (UPR) and autophagy, which I will describe in further detail in the following sections 
(Bu et al. 2018; Koyanagi et al. 2011; Igarashi et al. 2007; Huang et al. 2016; Fortini et al. 2016; 
W.-S. Lee et al. 2015; Masiero et al. 2009). Moreover, disruption of circadian oscillation has been 
shown to promote tumorigenesis in different cancer settings (S. Wu et al. 2016; Ha et al. 2016; Fu 
et al. 2002).  
 
Endoplasmic Reticulum (ER) Stress, the Unfolded Protein Response (UPR), and Muscle 
Differentiation 
The UPR is a signaling hub that is mediated by the three ER transmembrane receptors: 
RNA-dependent protein kinase-like ER eukaryotic translation initiation factor 2 alpha kinase 
(PERK), inositol-requiring protein 1 (IRE1), and activating transcription factor 6 (ATF6) (Hetz 
2012; M. Wang & Kaufman 2014; J. Wu & Kaufman 2006). The ER is membrane bound organelle 
composed of a network of branching tubules arranged in sacs that is responsible for synthesis, 
folding, processing and trafficking proteins (Isler et al. 2005; Pyrko et al. 2007; Welihinda et al. 
1999). ER stress is caused by different stimuli, such as protein misfolding, viral infections, 
imbalances in calcium levels, among others that may disrupt cell homeostasis, and can activate 
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the UPR via PERK, IRE1 and ATF6 receptors (Isler et al. 2005; Pyrko et al. 2007; Welihinda et al. 
1999).  
 
Prior to ER stress, the BiP/glucose-regulating protein 78 (GRP78) is bound to the UPR 
transmembrane receptors and renders them inactive (Harding et al. 1999; Hetz 2012; Y. Ma et al. 
2002). Upon ER stress, BiP is released and associates with misfolded proteins in the ER lumen. 
Once BiP is released, PERK is autophosphorylated and starts a signaling cascade by 
phosphorylating the eukaryotic translation initiation factor 2a (eIF2a) and subsequent translation 
of activating transcription factor 4 (ATF4), which in turn induces transcription of DNA damage-
inducible transcript 3 (Ddit3), which encodes C/EBP homologous protein (CHOP) (Harding et al. 
1999; Hetz 2012; Y. Ma et al. 2002). Once ER stress has been relived, the PERK pathway is 
involved in the termination of UPR signaling by activating GADD34 (Ron & Walter 2007) (Figure 
4, left). IRE1, another UPR transmembrane receptor, becomes activated during ER stress by 
autophosphorylation (Flamment et al. 2012). IRE1 promotes splicing of XBP1 mRNA, which in 
turn increases the amount of ER chaperones and other components, in order to increase the 
protein folding capacity of the ER (Tirasophon et al. 1998) (Figure 4, center). The third and last 
UPR transmembrane receptor is ATF6, which is cleaved and moves from the ER to the Golgi 
apparatus (Haze et al. 1999) (. The N-terminal of the cleaved ATF6 receptor translocates into the 
nucleus and in combination with spliced XBP1, increases proteins that alleviate ER stress 
(Flamment et al. 2012) (Figure 4, right). Once all three pathways are active, they alleviate ER 
stress by regulating gene expression and protein synthesis to increase the protein folding 
capacity of the cell (Harding et al. 1999; Hetz 2012; Y. Ma et al. 2002).  
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Figur
Figure 4: Unfolded protein response (UPR) signaling pathways  
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Recent studies have shown that ER stress-induced UPR is necessary for muscle 
regeneration and muscle mass maintenance (Bohnert et al. 2018; Xiong et al. 2017; Bohnert et 
al. 2016). The PERK and ATF6 translated protein, CHOP, is known to stall differentiation by 
repressing MyoD in order to prevent premature differentiation of muscle progenitor stem cells 
(Alter & Bengal 2011). The PERK arm of the UPR has been shown to promote myofiber formation 
and is potentially required for maintaining satellite cells in a quiescent state in adult skeletal 
muscle (Xiong et al. 2017; Zismanov et al. 2016). Moreover, the ATF6 arm of the UPR is known 
to promote apoptosis in myoblasts that may be susceptible to cellular stress during differentiation 
(Nakanishi et al. 2005; Nakanishi et al. 2007). Although there is evidence of the UPR’s 
contribution to skeletal muscle myogenesis and differentiation, the molecular mechanisms by 
which the UPR affects skeletal muscle differentiation remain to be elucidated.  
 
The UPR and circadian clock have been shown to exhibit significant crosstalk in various 
tissues and cancer types (Bu et al. 2018). In skeletal muscle and muscle-derived tumors both the 
UPR and clock can be simultaneously upregulated and are important for differentiation (Andrews 
et al. 2010; Xiong et al. 2017; Bohnert et al. 2016). Recently, the UPR was identified to directly 
regulate the clock by suppressing the BMAL1-CLOCK heterodimer (Bu et al. 2018). Specifically, 
in vitro studies show that the PERK pathway triggers a 10-hour shift in circadian oscillation by 
inducing expression of miR-211, which directly suppresses BMAL1 and CLOCK (Bu et al. 2018). 
The clock has also been shown to control ER stress in order to mediate liver senescence through 
expression of Pdia3 (Yuan et al. 2017). Moreover, it was also shown that inhibition of the 
PERK/ATF4 pathway allowed for malignant progression of various cancers (Hart et al. 2012; 
Huber et al. 2016; Qing et al. 2012). Whereas Per1 is regulated by the IRE1 pathway, Per2 is a 
transcriptional target of ATF4 (Pluquet et al. 2013; Koyanagi et al. 2011). Thus, the PERK/PER2 
axis could play an important role in preventing tumor initiation and progression.  
Another critical function of the UPR and the clock is the regulation of metabolic processes 
(Bohnert et al. 2018). Activation of ATF4 is necessary for glutathione synthesis, whereas 
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activation of IRE1 controls hepatic lipid metabolism (Igarashi et al. 2007; Cretenet et al. 2010). 
Thus, when the UPR and clock are hijacked there is a possibility that both pathways are helping 
support a shift in metabolism that allows for tumor formation. Additionally, there is significant 
crosstalk between the UPR and autophagy, an important catabolic signaling process that 
promotes cell survival (White 2015). This relationship will be discussed further in the next section. 
 
Autophagy and Muscle Differentiation 
Autophagy is a natural self-degradation and catabolic mechanism important for balancing 
cellular energy sources that promotes degradation or recycling of cellular components (Senft & 
Ronai 2015; Glick et al. 2010). Autophagy is known to preserve organelle function, prevent toxic 
buildup of cellular waste products, and provides substrates to sustain metabolism during 
starvation (White 2015). There are three types of autophagy, macroautophagy, microautophagy, 
and chaperone-mediated autophagy (Glick et al. 2010). For the purpose of this dissertation I will 
focus on macroautophagy, referred to as autophagy from here on. 
 
The autophagic machinery begins with the phagophore, an isolation membrane thought to 
arise from the ER membrane, the trans-Golgi, or endosomes (Axe et al. 2008; Simonsen & Tooze 
2009). The phagophore then becomes the autophagosome by engulfing intracellular proteins, 
organelles, and ribosomes (Mizushima 2007). Next, the autophagosome fuses with the lysosome 
to form the autophagolysosome, which contains lysosomal proteases that degrade its cargo 
(Mizushima 2007; Glick et al. 2010) (Figure 5). Last, nutrients and degradation products such as 
amino acids, are recycled and transported back into the cytoplasm by lysosomal permeases and 
transporters (Mizushima 2007).  
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Figure 5: Autophagy model  
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Autophagy also functions as a survival mechanism, as it can clear damaged organelles and 
intracellular pathogens (Glick et al. 2010). Moreover, autophagy is known to play a key role in 
cancer, neurodegenerative diseases, autoimmune diseases, among others, because it can 
promote cellular senescence, present cell surface antigens, protect against genome instability 
and DNA damage, and prevent necrosis (Young et al. 2009; English et al. 2009; Karantza-
Wadsworth et al. 2007; Degenhardt et al. 2006).  
 
Autophagy is controlled by over 30 autophagy related genes (ATG) that can be activated by 
lack of nutrients followed by inhibition of the mechanistic target of rapamycin (mTOR) signaling or 
by the UPR when misfolded proteins accumulate (Mizushima & Komatsu 2011; Deegan et al. 
2013). The PERK and IRE1 arms of the UPR have been implicated in activating autophagy 
(Haberzettl & Hill 2013; B'chir et al. 2013). Moreover, in ATG knockout mice, the IRE1 pathway 
was active and promotes inflammation, which supports a feedback mechanism between the UPR 
and autophagy (Deegan et al. 2013; Adolph et al. 2013). In an in vitro murine muscle-
differentiation system, it was shown that autophagy is induced during skeletal muscle 
differentiation (Fortini et al. 2016; Levine & Klionsky 2004). Not only is autophagy known to play 
an important role during bone marrow stem cell differentiation into osteocytes and adipocytes, but 
it has been shown that autophagy is required for muscle mass maintenance (Masiero et al. 2009; 
Nuschke et al. 2014). Last, mitophagy, or the selective degradation of mitochondria via 
autophagy, is required for myogenic differentiation in C2C12 myoblasts (Sin et al. 2016).  
 
Autophagy along with the UPR and circadian clock are known to govern metabolic 
processes. Disruption of these pathways can cause shifts towards a cancer associated glycolysis 
and promote cell hyperproliferation (Altman et al. 2015; Fortini et al. 2016; Carracedo et al. 2013). 
Moreover, it has been shown that autophagy suppresses tumorigenesis in some contexts, but in 
most contexts, autophagy facilitates tumorigenesis (White 2015; Liang et al. 1999; Takamura et 
al. 2011; Strohecker et al. 2013; Degenhardt et al. 2006; Guo et al. 2011; Lock et al. 2011). In 
  
    24   
some of these cancers, autophagy is upregulated to survive stress, and to promote tumor 
survival, growth and proliferation (Guo et al. 2011; Lock et al. 2011). Thus autophagy, the UPR 
and circadian clock potentially offer new therapeutic avenues to treat cancer.   
 
Summary 
In summary, the research described in this dissertation will focus on understanding the 
molecular mechanisms that promote UPS initiation, development, and proliferation. In particular, I 
sought to elucidate the mechanism by which YAP1 and NF-kB promote sarcomagenesis and 
disrupt cellular signaling networks important for skeletal muscle differentiation. My findings show 
the contributions of circadian clock signaling, the UPR, and autophagy have on UPS proliferation 
and muscle differentiation. For this dissertation, I employed different genetic and epigenetic tools 
as well as in vitro and in vivo models. 
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Chapter 2: Materials and Methods 
 
Genetically Engineered Mouse Models (GEMM). All mouse experiments were performed in 
accordance with NIH guidelines. All protocols and experiments were approved by the University 
of Pennsylvania Institutional Animal Care and Use Committee. We generated KrasG12D+; Trp53fl/fl; 
YAP1fl/fl (KPY) and KrasG12D+; Trp53fl/fl; Relafl/fl (KPR) mice by crossing KP with YAP1fl/fl and 
Relafl/fl animals. Tumors were generated by injection of a calcium phosphate precipitate of 
adenovirus expressing Cre recombinase (University of Iowa) into the right gastrocnemius muscle 
of 3- to 6-month-old mice.  
 
In vivo drug treatment. For in vivo drug studies, total 44 (n=11 per group) autochthonous KP 
mice were randomly divided into 4 groups to receive different treatments once tumors reached 
100 mm3 and injected for up to 20 days. The mice are euthanized 24 hrs after the tumor volume 
reaches 2000 mm3). 1) Vehicle group (10% Hydroxypropyl-β-cyclodextrin plus DMSO was diluted 
daily in sterile 45% PEG/55% H2O); 2). JQ1 and SAHA combination treatment group (drugs were 
diluted in respective vehicles). Treatment method for drug combination group: 1). 25mg/kg SAHA 
+ 50mg/kg JQ1 for first 5 days. 2) 25mg/kg SAHA+25mg/kg JQ1 each other day for 10days. 3). 
25mg/kg SAHA + 50mg/kg JQ1 for 2 days. 4). Then mice with tumors received 25mg/kg SAHA 
with 25mg/kg JQ1 for 3 days. Mice without tumors received 5mg/kg SAHA and 5mg/kg JQ1 for 3 
days). JQ1 was provided by Jun Qi (Dana-Farber Cancer Institute) and SAHA was purchased 
from Cayman Chemical. HP-β-CD and PEG400 were obtained from Sigma-Aldrich. 
 
Oncomine and TCGA survival analysis.  We used the publicly available database Detwiller et 
al. via the Oncomine Research Premium edition software (version 4.5, life Technologies) to query 
PER1, PER2, CRY1, CRY2, ARNTL, TXNIP, DDIT3, FASN, CPT1A, CPT1B gene expression in 
MFH/UPS. We also evaluated human patient survival using the TCGA sarcoma dataset. Kaplan-
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Meier analyses were performed for overall survival of patients. 
 
Cell Lines. KP230, KP250 and KIA cell lines were derived from UPS mouse tumors as described 
in {EisingerMathason:2013jn}. Human HT-1080, HEK-293T cell lines were purchased from ATCC 
(Manassas, VA, USA). STS-109 cell line was derived from human UPS patients. STR analysis 
was performed at the time of derivation and confirmed in April 2015. Cells were purchased, 
thawed, and then expanded in the laboratory. Multiple aliquots were frozen down within 10 days 
of initial resuscitation. For experimental use, aliquots were resuscitated and cultured for up to 20 
passages (4–6 weeks) before being discarded. Cells were cultured in DMEM with 10% (vol/vol) 
FBS, 1% penicillin/streptomycin, 1% glutamine, at 5% CO2 and 37°C.  All cell lines were 
confirmed to be negative for mycoplasma contamination. 
 
Drug Treatments. Cells were treated with SAHA (2µM) and JQ1 (0.5µM) either individually or in 
combination for the time indicated in the figure legends. Drugs were refreshed for any cells 
treated for longer than 48hrs. 
 
Lentiviral Transduction. shRNA-mediated knockdown of Per1: TRCN0000075403; Arntl: 
TRCN0000095055; Txnip: TRCN0000182360; Ddit3: TRCN0000103709; RelA: 
TRCN0000055344, TRCN0000055346; and Yap1: TRCN0000095864, TRCN0000095865 were 
obtained as glycerol stocks from Dharmacon. Scramble shRNA was obtained from Addgene. 
High-copy plasmid purification was conducted for each shRNA using Clontech Laboratories Inc. 
NucleoBond Exta Midi kit (740410.50) according to the NucleoBond ® Xtra Plasmid Purification 
Maxi protocol. shRNA plasmids were packaged by using the third-generation lenti-vector system 
(VSV-G, p-MDLG, and pRSV-REV) and expressed in HEK-293T cells. Supernatant was collected 
at 24 and 48 hrs after transfection and subsequently concentrated by using 10-kDa Amicon Ultra-
15 centrifugal filter units (Millipore). After 72 hours of lentiviral infection, cells were selected with 
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puromycin (1.5 µg/mL) for 24-48 hours. shRNA infected cells were treated with SAHA (2µM) and 
JQ1 (0.5µM) for 48 hours kept under puromycin selecting conditions.  
 
ChIP-seq. For tumor samples resected from UPS patients at the Hospital of the University of 
Pennsylvania, approximately 100 mg of tissue was minced into 1-2 mm pieces and incubated in 
1% formaldehyde for 15 minutes. Formaldehyde was quenched with glycine at 0.125 M. Fixed 
tissue was homogenized for 60 seconds with a Tissue Tearor Homogenizer (Biospec) at 30,000 
RPM. Homogenized tissue was washed with ice-cold PBS with 1X HALT protease inhibitor. For 
cell-line ChIP-RX, samples were fixed for 10 minutes in 1% formaldehyde quenched with glycine 
and washed with PBS as above. 5e6 S2 cells (Drosophila Melanogaster) were added to each 
sample of 2.5e7 for ChIP-RX normalization in downstream analysis.  
 
Transient Transfections. SMARTpool: ON-TARGETplus Yap1 siRNA (M-100439-01-0005), 
Cry2 siRNA (L-040486-00-0005), Per1 siRNA (L-040487-00-0005), and Non-targeting siRNA 
were purchased from Dharmacon.  
 
UPR Reporter Assays. KP cells were plated in a 6 well plate and transiently transfected using 
the LipofectamineTM3000 protocol. Cells were transfected using the Addgene plasmids ATF4 5: 
5’ATF4:GFP (#21852) and pEGFP-ATF6 (#32955). Fluorescence images were taken using 
Olympus IX2-UCB microscope, SensiCamQE High Perfomance camera, and X-Cite® Series 
120PC. Images were taken using the Slidebook 6 program.  
 
Immunoblots. Protein lysate was prepared in SDS/Tris (pH7.6) lysis buffer, separated by 
electrophoresis in 8-10% SDS/PAGE gels, transferred to nitrocellulose membrane, blocked in 5% 
non-fat dry milk, and probed with the following antibodies:  rabbit anti-PER1 (ab3443; 1:250), 
rabbit anti-CRY2 (ab38872, 1:500) (Abcam), rabbit anti-BMAL1 (14020S; 1:1000), rabbit anti-
YAP1 (4912; 1:1000), rabbit anti-GAPDH (2118; 1:1000), (Cell Signaling Technology), rabbit anti-
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CPT1A (15184-1-AP; 1:1000) (Proteintech), rabbi anti-TXNIP (ab188865, 1:1000) (Abcam), rabbit 
anti-CHOP (60304-1, Ig, 1:1000) (Proteintech),  rabbit anti-FASN (3081, 1:1000) (Cell Signaling 
Technology), anti-LC3A/B (12741, 1:1000) (Cell Signaling Technology), rabbit anti-Caspase-3 
(9662; 1:1000).  
 
qRT-PCR. Total RNA was isolated from tissues and cells using the TRIzol regent (Life 
Technologies) and RNeasy Mini Kit (Qiagen). Reverse transcription of mRNA was performed 
using the High-Capacity RNA-to-cDNA Kit (Life Technologies). qRT-PCR was performed by using 
a ViiA7 apparatus. All probes were obtained from TaqMan “best coverage" (Life Technologies). 
HPRT and or/ SDHA was used as an endogenous control.  
 
Luciferase assay. Plasmid pABpuro-BluF (46824; Addgene) was transfected into 293T cells 
(ATCC) to generate lentiviral particles in the supernatant. Viral supernatant was harvested and 
then concentrated by centrifugal filter units (Amicon Ultra-15, Millipore). Then Bmal reporter virus 
was transduced into KP230 cells. Positive Bmall reporter cells were selected by puromycin. For 
shRNA assays the Bmal reporter cell line was transduced with lentivirus expressing control or 
Yap1 shRNA. For drug studies, the Bmal reporter cells were treated with SAHA (2µM)/JQ1 
(0.5µM) on time course. Luciferase activity was assayed using the Dual Luciferase Assay System 
(E2920, Promega) according to the manufacturer’s protocol on a Luminometer (GLOMAX, 
Promega). Results were calculated as fold induction. 
 
Microarray and gene set enrichment analysis. Microarray services were provided by the 
UPENN Molecular Profiling Facility, including quality control tests of the total RNA samples by 
Agilent Bioanalyzer and Nanodrop spectrophotometry.  All protocols were conducted as 
described in the Affymetrix WT Plus Reagent Kit Manual and the Affymetrix GeneChip 
Expression Analysis Technical Manual. Briefly, 250ng of total RNA was converted to first-strand 
cDNA using reverse transcriptase primed by poly(T) and random oligomers that incorporated the 
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T7 promoter sequence. Second-strand cDNA synthesis was followed by in vitro transcription with 
T7 RNA polymerase for linear amplification of each transcript, and the resulting cRNA was 
converted to cDNA, fragmented, assessed by Bioanalyzer, and biotinylated by terminal 
transferase end labeling. Five and a half micrograms of labeled cDNA were added to Affymetrix 
hybridization cocktails, heated at 99ºC for 5 min and hybridized for 16 h at 45ºC to Mouse 
Transcriptome 1.0 ST GeneChips (Affymetrix Inc., Santa Clara CA) using the GeneChip 
Hybridization oven 645. The microarrays were then washed at low (6X SSPE) and high (100mM 
MES, 0.1M NaCl) stringency and stained with streptavidin-phycoerythrin. Fluorescence was 
amplified by adding biotinylated anti-streptavidin and an additional aliquot of streptavidin-
phycoerythrin stain. A GeneChip 3000 7G scanner was used to collect fluorescence signal. 
Affymetrix Command Console and Expression Console were used to quantitate expression levels 
for targeted genes; default values provided by Affymetrix were applied to all analysis parameters. 
Affymetrix cel (probe intensity) files were normalized and summarized using RMA-SST to the 
gene level using Expression Console software (v1.4.1). Inter sample variation was visualized 
using Principal Components Analysis in Partek Genomics Suite (v6.6, Partek, Inc., St. Louis, 
MO). Differential gene expression was tested using Significance Analysis of Microarrays (SAM, 
samr v2.0), yielding fold change, q-value (false discovery rate) and d-score for each gene. We 
observed a small number of genes meeting our cutoffs for differential expression and so 
proceeded to GSEA. Log2-transformed RMA-sst expression values were used as input to GSEA 
(Subramanian et al. 2005) where enrichment was tested against the hallmark gene sets from the 
Molecular Signatures Database (MSigDB, v5.1, 
http://software.broadinstitute.org/gsea/msigdb/index.jsp) 
 
Accession Codes. Sequencing data reported in this paper have been deposited in NCBI's Gene 
Expression Omnibus and are accessible through GEO Series accession numbers GSE109920, 
and GSE109923. 
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C2C12 growth and differentiation. C2C12 murine myoblast cells were obtained from ATCC 
(Manassas, VA, USA). The cells grow as undifferentiated myoblasts in growth medium (20% FBS 
with 1% penicillin/streptomycin) and were passaged every 2-3 days at 50% sub-confluence. To 
induce differentiation cells were grown overnight to ~80% confluence in growth medium, and then 
switched to DMEM supplemented with 2% horse serum. Differentiation media was refreshed 
every 2 days. 
 
Immunohistochemistry. Human UPS paraffin embedded tissues were obtained from the 
Surgical Pathology group at Univ. of Pennsylvania and stained TXNIP and CHOP. Murine tumors 
from the KP GEMM and KP allografts were also sectioned and stained. IHC was performed on 5-
micron tissue sections according to standard protocols. Sections were deparaffinized, rehydrated 
and subjected to epitope retrieval and stained with The following antibody concentrations were 
used: rabbit anti-TXNIP (ab188865; 1:100) (Abcam), mouse anti-CHOP (Proteintech) (60304-1-
IG; 1:250), rabbit anti-LC3B (Novus Biologicals; NB100-2220, 1:1000), rabbit anti-p62 (MBL 
International, PM045, 1:2000), mouse anti- Gadd34 (Novus Biologicals; NBP2-01787, 1:100) 
followed by peroxidase-based detection and counterstaining with hematoxylin using the Leica 
Bond Rxm system with conditions described previously (Berezowska & Galván 2017). 
Representative photographs were taken on a Leica DMI6000B inverted light and fluorescent 
microscope with a 40x oil objective. Images were blinded, and positive staining was assessed in 
Image J. The color deconvolution macro was applied to images resulting in a DAB staining 
(Color_2) generated window (Ruifrok & Johnston 2001). Using the threshold function, the total 
area of the tumor in pixels was recorded utilizing the same parameters for each tumor image. 
Areas staining positive by these parameters were selected and the positive-staining area in pixels 
was recorded. The positive-staining area of the tumor in pixels was divided by the total area of 
the tumor in pixels to determine the percentage positive-staining area.  
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GC/MS. After growth overnight, cultures were treated with either DMSO or 2 μM SAHA/ 0.5 μM 
JQ1. The cultures were allowed to grow for 48 hours.  Subsequently, the medium was changed to 
DMEM that contained 7 mM glucose, 4 mM glutamine, 75 µM [U-13C16]palmitic acid and 75 µM 
[U-13C18]oleic acid plus either DMSO or S/J.  Both fatty acids were bound to fatty acid free 
albumin (2 moles fatty acid per mole of albumin) before they were added to the medium.  After 12 
hours of growth in the 13C-labeled medium, the cultures were harvested by cold methanol 
extraction.  The cold methanol (80:20 methanol:water) was pre-cooled to -80C and added rapidly 
(2 ml/dish) after removal of the extraceullar medium to prevent loss of intracellular metabolites.  
The cultures were stored at -80C prior to gas chromatography/mass spectrometry analysis 
(GC/MS) analysis. The methanol/cell mixtures were sonicated for 60 seconds with a probe 
sonicator to disrupt all cell membranes and then centrifuged at 13,000xg for 10 minutes.  The 
supernatants were removed and transferred to sealable 4-ml glass tubes.  Methanol and water 
were removed from the cell extracts with a heated (45C) nitrogen evaporator. For GC/MS, the 
extracts were first derivatized with N,O-Bis(trimethylsilyl) trifluoroacetamide (BSTFA). The 
extracts in the 4-ml glass tubes were dissolved in 60 µL of pyridine.  Subsequently, 60 µL BSTFA 
with 1% trimethylchlorosilane (Sigma-Aldrich, St. Louis, MO) were added and the mixtures were 
heated to 55C for 60 min.  After cooling, the reaction mixtures were centrifuged at 13,000xg for 5 
minutes.  The supernatant was transferred to 1.5 ml capped injection vials that were fitted with 
volume reducing glass sleeves. The derivatized samples were analyzed with an Agilent 
7890A/5975C GC/MS system. Mass fragments were generated by electron impact at 70eV. 
Helium was used as the carrier gas for the GC DB-5 column (30 m, with 10 m empty pre-column) 
at a flow rate of 1 ml/min. The injector was operated in splitless mode at 250C. The column 
temperature profile was 0-3 min: 100C, 3-17 min: ramp 10C/min, 17-47 min: 240C, 47-52min: 
300C. The citrate retention time was 24.1 minutes. The mass scan range was 50 to 550 daltons. 
The relative enrichment of metabolites was calculated using IsoCor (Millard et al. 2012). 
 
  
    32   
Statistical Analysis. Statistical analysis was performed using Prism (Graph Pad Software). Data 
are shown as mean ± SEM or SD. Data were reported as biological replicates. Experiments were 
performed in triplicate. Student t-tests (unpaired two tailed) were performed to determine whether 
a difference between two values is statistically significantly different, with a P-value <0.05 
considered significant. 
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Chapter 3: YAP1 enhances NF-kB-dependent and independent 
effects on clock-mediated unfolded protein response and 
autophagy in sarcoma 
 
Introduction 
Soft-tissue sarcomas (STS) are a complex set of tumors that arise in mesenchymal 
tissues, including muscle, fat, cartilage and connective tissue. The roughly 65 known sarcoma 
subtypes can be generally divided into two groups 1) majority pediatric sarcomas which most 
frequently develop as a result of chromosomal translocations (Kadoch & Crabtree 2013; 
Ciarapica et al. 2014; Shern et al. 2014) and 2) typically adult sarcomas that have no known 
consistent oncogenic mutations, but ~50% of which bear mutations in tumor suppressor genes 
like RB1 or p53 (W. Lee et al. 2014; De Raedt et al. 2014; M. Zhang et al. 2014). Due to their 
karyotype complexity, variety of subtypes, and the lack of known drivers, adult sarcomas are very 
poorly understood. Treatment options are generally limited to radiation and surgery, as 
inadequate characterization has precluded the development of targeted therapies (Pappo et al. 
2014; Wagner et al. 2015; Taylor et al. 2011). Our current work focuses on undifferentiated 
pleomorphic sarcoma (UPS), an aggressive adult tumor found in skeletal muscle. Muscle-derived 
UPS is a commonly diagnosed subtype relative to other sarcomas and is particularly difficult to 
treat (Ballinger et al. 2016). Patients rely on radiation and resection, which can be traumatic and 
frequently fails to prevent metastasis. My work shows that the central Hippo effector, Yes 
associated protein 1 (YAP1), is stabilized in human UPS tumors and promotes a pro-proliferation 
transcriptional program (Mizuno et al. 2012; Ye et al. 2018). YAP1 is unusually stable in UPS and 
potentially other sarcomas due to epigenetic silencing of its inhibitor, Angiomotin (AMOT), and 
Hippo kinase copy number loss (Rubin et al. 2011; Eisinger-Mathason et al. 2015). These 
perturbations stabilize YAP1 at the protein level; enhance its nuclear localization and subsequent 
transcriptional activity (Ye et al. 2018). 
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Though well studied in epithelial tumors, the specific downstream effectors of YAP1 in 
sarcomas are not well characterized. Skeletal muscle-derived UPS is thought to develop from 
muscle progenitor cells/satellite cells, which undergo proliferation as immature myoblasts before 
differentiating into mature muscle fibers. YAP1 and NF-kB signaling are essential for myoblast 
proliferation and these pathways must be inhibited to permit terminal differentiation (Rubin et al. 
2011; Watt et al. 2010; Tubaro et al. 2010; Bakkar et al. 2008; Dogra et al. 2006; Ardite et al. 
2004). Thus, during normal muscle development inhibition of NF-kB and YAP1 are associated 
with loss of proliferative capacity, and upregulation of muscle differentiation markers like MYOD 
and MEF2C. Recently we discovered that YAP1 controls NF-kB activity in muscle-derived UPS, 
by inhibiting expression of Ubiquitin Specific Peptidase 31 (USP31) a negative regulator of NF-kB 
(Ye et al. 2018). In the absence of a specific inhibitor for YAP1 we used a combination of the 
epigenetic modulators suberoylanilide hyroxamic acid (SAHA; Vorinostat), and the BET 
bromodomain inhibitor JQ1, which we recently discovered effectively suppresses YAP1 activity by 
upregulating the YAP1 cytoplasmic sequestration protein AMOT and reducing YAP1 expression. 
Though SAHA/JQ1 treatment has widespread effects, we use these tools to interrogate and then 
validate YAP1-mediated signaling and phenotypes. Importantly, SAHA/JQ1 treatment 
upregulated a transcriptional program associated with muscle differentiation in these tumors. 
Consistently, here we report that shRNA-mediated inhibition of YAP1 and/or NF-kB recapitulates 
several key aspects of SAHA/JQ1-mediated differentiation.  
 
Interestingly, we observed that (Zambrano et al. 2016; X. Wang et al. 2015). Consistent 
with these findings, normal myoblast proliferation and muscle differentiation have been linked to 
peripheral circadian oscillation (Andrews et al. 2010; X. Zhang et al. 2009; McCarthy et al. 2007). 
The circadian clock is a 24-hour molecular signaling hub that regulates proliferation via control of 
metabolic processes and is regulated by positive and negative feedback loops (Bass & Takahashi 
2010; Huang et al. 2016; Bell-Pedersen et al. 2005; Lowrey & Takahashi 2004). The main 
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transcriptional components, CLOCK and BMAL1, form a heterodimer that binds to an E-box in the 
promoters of target genes, such as PERIOD (PER) and CRYPTOCHROME (CRY), promoting 
their expression, which in turn inhibit CLOCK and BMAL1 heterodimers (Lowrey & Takahashi 
2004; Ripperger & Schibler 2006). Shuttling of PER and CRY proteins from the cytoplasm to the 
nucleus regulates the feedback loop. Importantly, a growing body of literature suggests that 
disruption of circadian oscillation promotes tumorigenesis in a variety of cancer settings (S. Wu et 
al. 2016; Ha et al. 2016; Fu et al. 2002).  
 
Recent studies have shown that clock activity is linked to a number of pathways 
associated with muscle differentiation including the Unfolded Protein Response (UPR) (Bu et al. 
2018; Igarashi et al. 2007; Huang et al. 2016; Fortini et al. 2016; W.-S. Lee et al. 2015; Masiero et 
al. 2009). Crosstalk between (Margariti et al. 2013; Gade et al. 2012; Rzymski et al. 2010) . 
Importantly, YAP1 plays a role in cancer related autophagic flux a(Q. Song et al. 2015; H. Wu et 
al. 2015). Based on these observations we hypothesized that YAP1 and/or NF-kB helps control 
differentiation in muscle tissues and tumors via regulation of the circadian clock and downstream 
processes. My work demonstrates that the YAP1/NF-kB axis controls the switch between 
differentiation and proliferation in sarcoma by suppressing the circadian clock and UPR. 
Interestingly, I observed that YAP1 also suppresses autophagy but in an NF-kB-independent 
manner. 
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Results 
Clock gene expression is high in differentiating muscle and lost in UPS 
We investigated the role of YAP1 in UPS, by silencing it in our genetically engineered 
murine model (GEMM) of UPS. We introduced Yap1fl/fl alleles into the LSL-KrasG12D/+; Trp53fl/fl 
(KP) system to generate LSL-KrasG12D/+; Trp53fl/fl; Yap1fl/fl (KPY) animals. The KP model 
generates sarcomas that recapitulate human UPS and is thus the standard GEMM used in these 
studies (Kirsch et al. 2007; Mito et al. 2009). Importantly, Yap1 protein expression is stabilized in 
KP tumors5, which provides further rationale for the study of Yap1 in sarcoma using this model 
(Ye et al. 2018). Injection of adenovirus expressing Cre recombinase into the right gastrocnemius 
muscle initiates tumorigenesis. The Cre recombinase activates expression of oncogenic Kras 
while simultaneously deleting p53 and/or Yap1 in infected muscle progenitor cells (Kirsch et al. 
2007; Mito et al. 2009). Though Kras mutation is rare in human sarcomas, Trp53 mutation and 
deletion are very common (Cancer Genome Atlas Research Network. Electronic address: 
elizabeth.demicco@sinaihealthsystem.caCancer Genome Atlas Research Network 2017). 
Additionally, hyperactivation of the MAPK pathway, downstream of KRAS activation, is also 
common in UPS and is an excellent prognostic indicator for recurrence (Serrano et al. 2016). 
Yap1 loss in KPY tumors increases latency and reduces tumor weight and volume (Ye et al. 
2018). To determine the functional role of Yap1 in UPS we performed microarray analysis of 5 
individual KP and KPY tumors. In addition to suppression of NF-kB targets (Ye et al. 2018), we 
observed differential expression of the circadian clock genes Per1, Per2, Cry1, Cry2 and Arntl 
(Figure 6a), validated by qRT-PCR of RNA isolated from the murine tumors (Figure 6b). 
Because circadian clock function is important for skeletal muscle mass maintenance (Kondratov 
et al. 2006) and CLOCK and BMAL1 regulate MYOD, the master regulator of muscle 
differentiation (Andrews et al. 2010), we next queried clock gene expression in differentiating 
myoblasts using the C2C12 system. In C2C12 murine myoblasts, differentiation media containing 
2% horse serum activates myogenesis (Figure 6c). We observed an increase in expression of 
the Yap1 inhibitor Amot, clock genes (Per1, Per2) and the NF-kB negative regulator, Usp31 in 
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differentiated C2C12 cells (Figure 6d). Per1 and Per2 protein expression corresponded to loss of 
Yap1 in differentiating C2C12 cells (Figure 6e), indicating that the circadian clock is upregulated 
during muscle differentiation. Using Oncomine we queried publicly available sarcoma datasets for 
expression of PER1, PER2, and CRY2 in fibrosarcoma (FS) and UPS. Some fibrosarcomas, 
including myxofibrosarcomas (MFS), are now thought to be genetically indistinguishable from 
UPS (Cancer Genome Atlas Research Network. Electronic address: 
elizabeth.demicco@sinaihealthsystem.caCancer Genome Atlas Research Network 2017) and are 
therefore included in our studies. We found that clock genes are suppressed in these tumors 
compared to skeletal muscle and other normal tissues (Figure 6f-h). Together, these data 
suggest that Yap1 represses clock gene expression in muscle-derived UPS and that circadian 
clock is important for muscle differentiation. Based on these observations we hypothesized that 
expression of one or more circadian genes is linked to survival of patients with UPS/MFS. Based 
on these observations we hypothesized that expression of one or more circadian genes is linked 
to survival of patients with UPS/MFS. 
 
We investigated the relationship between long-term survival and expression of PER1 or 
CRY2, which are most consistently upregulated by YAP1/NF-kB loss in our studies. Importantly, 
our analysis of human MFS samples from The Cancer Genome Atlas (TCGA) showed that low 
levels of CRY2 are associated with poor survival (Figure 7a). To assess CRY2 expression in 
these tumors, relative to normal muscle, we performed RNA-seq and ChIP-seq of human skeletal 
muscle and multiple human UPS samples. CRY2 expression is suppressed in UPS tumors 
compared to muscle (Ye et al. 2018). Consistent with this finding we found that enrichment of 
Histone 3-lysine 27 Acetylation (H3K27Ac) is lost in UPS relative to skeletal muscle at the CRY2 
locus (Figure 7b). H3K27Ac enrichment is associated with active transcription and potential 
enhancer activity. The PER1 locus shows a similar pattern of H3K27Ac enrichment/gene 
expression in muscle and loss in UPS (Figure 7c) but there was no statistically significant link 
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between PER1 and patient survival, suggesting the relatively low number samples may be 
affecting our analysis in some cases. 
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Figure 6: Yap1-dependent inhibition of circadian clock genes in UPS and proliferating 
myoblasts  
A) Gene expression analysis of microarray performed on KP vs. KPY mouse tumors. 
B) qRT-PCR validation of circadian clock gene expression in KP and KPY mouse tumors.  
C) qRT-PCR of muscle differentiation genes. 
D) qRT-PCR of Hippo/NF-kB/Circadian clock genes in proliferating (Day 0, D0) and 
differentiating (D1-D6) C2C12 myoblasts.  
E) Western blot of Per1 and Per2 in C2C12 cells treated as in D.  
F) Oncomine gene expression analysis of PER1 in human tissues. 
G) Oncomine gene expression analysis of PER2 in human tissues. 
H) Oncomine gene expression analysis of CRY2 in human tissues. 
*Shaui Ye, Gloria Marino, Shaun Egolf, Gabrielle E. Ciotti, Ying Liu, and Susan Chor helped by performing experiments 
and analyzing data. 
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Figure 7: Clock genes in human UPS tumors  
A) Kaplan Meier survival curve of MFS patients in the TCGA sarcoma dataset based on 
CRY2 expression.  
B) Gene tracks of H3K27ac ChIP-seq signal (rpm/bp) for H3K27ac at the CRY2 locus in 
human skeletal muscle and human 3 independent human UPS samples. Error bars 
represent SD. 
C) Gene tracks of H3K27ac ChIP-seq signal (rpm/bp) for H3K27ac at the PER1 locus in 
human skeletal muscle and human 3 independent human UPS samples. 
*Shuai Ye and T.S. Karin Eisinger helped by performing experiments and analyzing data. John Tobias assisted in the data 
analysis. Human tumor samples were provided by Kristy Weber. 
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YAP1 suppresses circadian clock gene expression in UPS 
We previously reported that YAP1 expression and transcriptional activity is 
downregulated in sarcoma cells treated with SAHA/JQ1 in vitro and in vivo and that ectopic 
expression of constitutively nuclear YAP1 (YAPS6A mutant) can rescue ~40 of the proliferation 
defects associated with epigenetic modulation (Ye et al. 2018). Based on these observations, we 
hypothesized that SAHA/JQ1 treatment would reactivate clock gene expression due to loss of 
YAP1. Thus, we performed microarray analysis and compared gene expression in untreated vs. 
SAHA/JQ1 treated KP cells derived from KP tumors. We observed differential expression of 
circadian clock genes (Figure 8a). We further validated Per1, Cry2, and Arntl (Arntl encodes the 
protein Bmal) upregulation via qRT-PCR (Figure 8b) and Western blot (Figure 8c) of KP and 
human UPS cells (STS-109) (Figure 8d and e). PER1 mRNA levels also increased in SAHA/JQ1 
treated HT-1080 human fibrosarcoma cells (Figure 8f). The subset of clock genes regulated by 
YAP-deletion (KPY) in vivo and SAHA/JQ1-treatment in vitro varied slightly. We hypothesized 
that this target variation was due to the difference in approaches we expressed YAP1-specific 
shRNAs in KP cells and evaluated clock targets. We found that YAP1 inhibition phenocopied 
SAHA/JQ1 treatment in vitro (Figure 8g). We went on to validated PER1 and CRY2 antibodies, 
using siRNA to determine the appropriate Western blot bands (Figure 8h and i). 
 
To determine if YAP1 inhibition functionally induces clock activity we performed a Bmal 
luciferase reporter assay in KP cells using Yap1-specific siRNA, shRNA and SAHA/JQ1 (Figure 
9a-c). We observed increased Bmal reporter expression in all three systems, indicating that 
Bmal/circadian clock activity is under the control of YAP1. To verify that clock activity is 
responsible for inhibition of proliferation in Yap1-depleted cells we performed an in vitro rescue 
assay using a combination of Yap1-specific and Arntl-specific shRNAs. We observed a ~40% 
proliferation rescue in double knockdown cells relative to cells expressing YAP1 shRNA alone 
(black bar vs. gray bar) (Figure 9d, left), which correlated with a ~40% reduction of Arntl in 
double knockdown cells relative to cells expressing YAP1 shRNA alone (Figure 9d, right and 
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9e) (black bar vs. gray bar). Previously, we reported that Yap1-depletion promotes muscle-like 
differentiation (Ye et al. 2018). Here we report that Yap1 loss enhances cell cycle arrest in KP 
cells (Figure 9f). The number of KP cells in S phase drops 20-45% in cells expressing Yap1 
shRNAs. We conclude that the percentage of cells arrested outside of S-phase is roughly 
equivalent to the percentage of cells rescued by inactivation of the clock. Yap1 is also known to 
inhibit apoptosis via upregulation of Survivin/Birc5. Consistently, we have observed that 
SAHA/JQ1 treatment abolishes Birc5 expression. Therefore, we interrogated the role of Yap1 in 
apoptosis in KP cells. We found that shRNA-mediated inhibition of Yap1 expression increased 
cleavage of caspase 3, indicating enhanced apoptosis (Figure 9g). Importantly, apoptotic cells 
are unlikely to re-enter the cell cycle in response to Arntl suppression (Figure 9d and e). Thus, 
while our rescue phenotype may appear modest, we conclude that we are rescuing a significant 
fraction of non-apoptotic cells. Together, these data suggest that Yap1-mediated repression of 
clock gene expression promotes cell cycle progression and suppresses apoptosis, leading to an 
overall increase in cell numbers. Inhibition of clock function can partially reverse this phenotype, 
highlighting the importance of circadian function is UPS proliferation. 
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Figure 8: Yap suppresses clock gene expression 
A) Gene expression analysis of microarray performed on KP cells treated with 2 μM SAHA/ 
0.5 μM JQ1 for 48 hrs.  
B) qRT-PCR validation of clock genes in KP cells treated as in A.  
C) Western blot of KP cells treated as in A.  
D) qRT-PCR of human UPS cells (STS-109) treated as in A.  
E) Western blot of STS-109 cells treated as in A.  
F) qRT-PCR of HT-1080 cells treated with 2 μM SAHA/ 0.5 μM JQ1 for 48 hrs.  
G) qRT-PCR of KP cells expressing YAP1 shRNA.   
H) Western blot of KP cells treated as in B with or without PER1 siRNA to identify the correct 
band.  
I) Western blot of KP cells treated as in B with or without Cry2 siRNA to identify the correct 
band. 
*Shaui Ye, Gloria Marino, Shaun Egolf, Gabrielle E. Ciotti, and Susan Chor helped by performing experiments and 
analyzing data. 
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Figure 9: Yap-mediated suppression of the clock enhances sarcoma proliferation 
A) (left) Bmal luciferase reporter assay in KP cells expressing Yap1 siRNA (20nM) and 
treated with 2 μM SAHA/ 0.5 μM JQ1 for 12 hrs to activate signaling. (right) Western blot 
of YAP1 levels in siRNA treated cells.  
B) Bmal luciferase reporter assay in KP cells treated with 2 μM SAHA/ 0.5 μM JQ1.  
C) Bmal luciferase reporter assay in KP cells expressing Yap1 shRNA.  
D) (left) Cell counting rescue proliferation assay in Yap1#1 and Arntl shRNA expressing KP 
cells. (right) qRT-PCR of Yap1 and Arntl expression in KP. 
E) (left) Cell counting rescue proliferation assay in Yap1#2 and Arntl shRNA expressing KP 
cells. (right) qRT-PCR of Yap1 and Arntl expression in KP cells treated as in D. 
F) Representative flow cytometry plots and quantitation of BrdU incorporation in HT-1080 
cells expressing multiple independent YAP1 shRNAs. 
G) Western blot of KP cells expressing multiple YAP1 shRNAs and treated with 1 μM 
Staurosporin (12 hr) as positive control. Error bars represent SD. 
*Shaui Ye, Gabrielle E. Ciotti, and Susan Chor helped by performing experiments and analyzing data. 
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Circadian clock genes are regulated by NF-kB downstream of YAP1 
We previously reported that YAP1 enhances proliferation in part via upregulation of 
persistent NF-kB signaling (Ye et al. 2018). Here we interrogated the role of NF-kB in UPS 
initiation using the KP system. We bred Relafl/fl mice into our KP model and found that genetic 
deletion of NF-kB, encoded by the Rela gene prevents outgrowth of tumors (Figure 10a and b). 
These findings are in agreement with our earlier observation that expression of p65 specific 
shRNAs reduces KP tumorigenesis in an in vivo allograft model (Ye et al. 2018). NF-kB activity is 
directly linked to p65 phosphorylation because p65 is a critical subunit of the NF-kB transcription 
factor. Phosphorylated p65 translocates to the nucleus and promotes transcription. Both KP 
tumors and subcutaneous xenografts of human UPS cells stain positively for YAP1 and p-p65, 
supporting the hypothesis that this signaling axis is critical for growth in human and murine UPS 
and can be modeled with these tools (Figure 10c). Using pharmacological and genetic 
approaches we investigated whether YAP1 repression of clock genes is mediated by NF-kB 
activity. NF-kB inhibition with BAY 11-7085 (1 µM) for 48 hours increased Per1, Cry2, and Arntl 
mRNA expression (Figure 10d). shRNA-mediated Rela inhibition recapitulates this finding 
(Figure 10e). Importantly, NF-kB target expression oscillates over time in differentiating 
myoblasts (Ye et al. 2018) and other cells (Zambrano et al. 2016). YAP1 suppresses NF-kB 
oscillation by controlling expression of USP31 (Ye et al. 2018). Based on these findings, and our 
observation that Usp31 also oscillates in differentiating C2C12 cells (Figure 10d), we 
hypothesized that USP31 might oscillate on a 24-hour clock upstream of circadian clock gene 
expression. We treated human STS-109 (Figure 10f), KP, and HT-1080 cells (Figure 10g) with 
SAHA/JQ1 for 0-120 hours and found that treatment restores oscillation of USP31 in all three 
UPS cell lines. Interestingly the period of oscillation varies with the proliferation rate of the cells. 
Slower proliferation rates (KP>HT-1080>STS-109) correlate with shorter time to maximal USP31 
induction by SAHA/JQ1. Ultimately Usp31 levels are lost in KPY tumors relative to KP (Figure 
10h and i). This finding is consistent with our Bmal luciferase reporter assay in which we observe 
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that SAHA/JQ1 treatment initially induces clock activity, which then returns to low levels (Figure 
9a). Our findings suggest the provocative hypothesis that NF-kB oscillation may drive the 
circadian cycle in muscle and muscle-derived sarcoma subtypes. To verify that clock activity is 
responsible for loss of proliferation in NF-kB-depleted cells we performed an in vitro rescue assay 
using a combination of Rela-specific and Arntl-specific shRNAs (Figure 10j and k). We observed 
a ~20% increase in proliferation (black bar vs. gray bar) (Figure 10j, left), which correlates with a 
~40% reduction of Arntl in double knockdown cells (black bar vs. gray bar) (Figure 10j, right). 
Similarly, we applied BAY 11-7085 (1 µM) for 72 hours to KP cells expressing Arntl specific 
shRNA. BAY treatment dramatically decreased cell proliferation. Importantly, Arntl inhibition 
rescued a significant amount of proliferation in BAY treated KP cells (Figure 10k). These data 
indicate that Rela-mediated suppression of the clock enhances proliferation, a process that can 
be partially reversed by inhibiting clock function. We conclude that NF-kB activity controls 
tumorigenesis in this system, which may be due in part to regulation of the circadian clock. 
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Figure 10: Inhibition of NF-kB, downstream of Yap1, restores clock gene expression 
A) Rela deletion in the KP autochthonous model of UPS (n=18 mice per group. Log-Rank 
Chi-sq).  
B) Genotyping of KP and KPR mice. Kras band indicates the presence of the KrasG12D 
mutant allele, p53 bands indicate wt and fl/fl alleles. RelA band indicates the presence of 
the fl/fl alleles.  
C) IHC of KP and human xenograft UPS tumors.  
D) qRT-PCR of KP cells treated with NF-kB inhibitor 1.5 μM BAY 11-7085 for 12, 48 hrs.  
E) qRT-PCR of clock genes in KP cells expressing Rela shRNA.  
F) (left) qRT-PCR and (right) Western blot of USP31 expression in 2 μM SAHA/ 0.5 μM JQ1 
treated STS-109.  
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G) qRT-PCR of KP and HT-1080 cells treated with DMSO or 2 μM SAHA/ 0.5 μM JQ1 for 0-
120 hrs. 
H) Gene expression analysis of microarray performed on KP vs. KPY mouse tumors. The 
NF-kB target, Phlda1, is included as a control.  
I) qRT-PCR validation of Usp31 gene expression in KP and KPY mouse tumors.  
J) (left) Cell counting rescue proliferation assay in Rela and Arntl shRNA expressing KP 
cells. (right) qRT-PCR of Rela and Arntl expression in KP cells treated as in left.  
K) Cell counting rescue proliferation assay in Arntl shRNA expressing KP cells treated with 
1.0 μM BAY 11-7085 for 72 hr. Data is expressed as mean fold change and SEM relative 
to the cell numbers in samples treated for with DMSO or BAY for 24 hrs. Error bars 
represent SD. 
*Shaui Ye, Gabrielle E. Ciotti, and Susan Chor helped by performing experiments and analyzing data. Human tumor 
samples were provided by Kristy Weber. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    49   
YAP1/NF-kB loss initiates a muscle differentiation-associated UPR response 
Recent studies have established a link between the UPR and the clock (Bu et al. 2018; 
Yuan et al. 2017). Based on these observations and our finding that SAHA/JQ1 treatment 
activates clock genes (Figure 8a) we evaluated UPR activity and found that SAHA/JQ1 treatment 
also upregulates multiple UPR target genes based on microarray analyses (Figure 11a). 
Transcription of multiple PERK and ATF6- associated UPR targets were upregulated. We 
validated induction of PERK and ATF6 pathways; two of three UPR branches, in SAHA/JQ1 
treated cells (left) and cells expressing multiple independent Yap1 shRNAs (right) via qRT-PCR 
(Figure 11b). The third branch is IRE1-dependent. However, we did not observe mRNA 
upregulation or splicing in the IRE1 pathway specific target, Xbp1 (Figure 11c). Txnip and Ddit3, 
which encodes the UPR target Chop, are well studied PERK and ATF6 transcriptional targets. 
Importantly, these targets are two of the most differentially expressed genes from the DMSO vs. 
SAHA/JQ1 microarray. Using Oncomine, we observed that Txnip and Ddit3 expression are 
elevated in skeletal muscle and other tissues, but are suppressed in fibrosarcomas and UPS, 
suggesting that the UPR antagonizes sarcomagenesis in muscle-derived tumors (Figure 11d 
and e). Consistent with these observations, TXNIP and CHOP protein expression are elevated in 
SAHA/JQ1 treated KP and HT-1080 cells (Figure 11f-i). We sought to determine if Txnip and 
Ddit3 transcription are regulated specifically by YAP1. We inhibited Yap1 with specific shRNAs 
and observed increased Txnip and Ddit3 expression (Figure 11i). 
 
To confirm upregulation of UPR targets in muscle specifically, we evaluated Txnip and 
Ddit3 in our C2C12 model of myoblast differentiation and observed increased expression in 
differentiated cells (Figure 12a). To determine if NF-kB mediates Txnip and Ddit3 expression 
downstream of Yap1 we treated KP cells with BAY 11-7085 or expressed Rela shRNAs and 
observed an increase in Txnip and Ddit3 mRNA expression (Figure 12b and c). Next, we 
performed a rescue experiment to determine if YAP1-mediated suppression of the circadian clock 
controls expression of Txnip and Ddit3. We treated KP cells with SAHA/JQ1 and Per1 shRNA 
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alone or in combination. Interestingly, Txnip induction is similarly dependent on clock activity, 
whereas Ddit3 expression is not (Figure 12d) indicating that Ddit3 regulation may have clock-
independent aspects. Importantly, this observation agrees with our evaluation of Txnip and Ddit3 
levels in differentiating C2C12 cells, wherein Txnip oscillates during a 6-day differentiation time 
course but Ddit3, simply increases at each time point (Figure 12a). To ascertain the functional 
role of key UPR targets in SAHA/JQ1-induced differentiation we silenced Txnip and Ddit3 with 
specific shRNAs. We observed that loss of Txnip increases the expression of Ddit3 and the 
converse is true as well (Figure 12e). Therefore, we silenced both Txnip and Ddit3 in SAHA/JQ1 
treated cells to prevent compensation. Loss of Txnip and Ddit3 in SAHA/JQ-treated cells alters 
the normally cytostatic effects of these inhibitors and results in cell death, suggesting that UPR 
activation supports cell survival in differentiating muscle and sarcoma cells (Figure 12f and g). 
Thus, we conclude that the Yap1/NF-kB axis represses activation of targets in the PERK and 
ATF6 arms of the UPR, which are associated with clock activity and survival during differentiation 
(Bu et al. 2018; Yuan et al. 2017; Bohnert et al. 2018; Xiong et al. 2017).  
 
 
 
 
 
  
    51   
Figure 11: Inhibition of YAP1 and NF-kB activates UPR target gene expression 
A) Gene expression analysis of microarray performed on KP cells treated with 2 μM SAHA/ 
0.5 μM JQ1 for 48 hrs.  
B) qRT-PCR validation of UPR genes in (left) KP cells treated as in A and (right) with 
multiple independent YAP1 shRNAs. 
C) qRT-PCR of KP cells treated with 2 μM SAHA/ 0.5 μM JQ1 for 48 hrs. 
D) Oncomine gene expression analysis of TXNIP in human tissues. 
E) Oncomine gene expression analysis of DDIT3 in human tissues.  
F) Western blot of TXNIP in KP cells treated as in A. 
G) Western blot of TXNIP in HT-1080 cells treated as in A.  
H) Western blot of CHOP in HT-1080 cells treated as in A.  
I) qRT-PCR of Txnip and Ddit3 in KP cells expressing two independent Yap1 shRNAs. 
Error bars represent SD. 
*Shaui Ye, Susan Chor, and Jaimarie Sostre-Colón helped by performing experiments and analyzing data. 
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Figure 12: Txnip and Ddit3 are necessary for survival during muscle differentiation 
A) qRT-PCR for Txnip and Ddit3 genes in proliferating (Day 0, D0) and differentiating (D1-
D6) C2C12 myoblasts.  
B) qRT-PCR of KP cells treated with NF-kB inhibitor 1.5 μM BAY 11-7085 for 48 hrs.  
C) qRT-PCR of Txnip and Ddit3 in KP cells expressing Rela shRNAs.  
D) qRT-PCR rescue assay of KP cells expressing Per1 shRNA and treated with 2 μM 
SAHA/ 0.5 μM JQ1 for 48 hrs.  
E) qRT-PCR of KP cells expressing Txnip or Ddit3 shRNAs treated with 2 μM SAHA/ 0.5 μM 
JQ1 for 48 hrs.  
F) Cell counting rescue proliferation assay in cells expressing both Txnip and Ddit3 shRNAs 
and treated as in A. D/T shRNAs denotes Ddit3 and Txnip shRNAs were used for 
knockdown.  
G) Cell counting proliferation assay of KP cells from M from 0-96 hrs. Error bars represent 
SD. 
*Gabrielle E. Ciotti and Susan Chor helped by performing experiments and analyzing data. 
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SAHA/JQ1 treatment promotes oscillation of UPR target genes 
To further explore the link between the UPR and circadian oscillation we characterized 
the expression pattern of TXNIP and DDIT3 in both UPS and fibrosarcoma cells. TXNIP mRNA 
expression exhibited a dramatic circadian-like oscillation pattern with high amplitude changes in 
KP and HT-1080 cells over 0-120hrs of treatment with SAHA/JQ1, whereas the amplitude of 
DDIT3 oscillations were more limited (Figure 13a-d). Importantly, these substantial oscillations 
were only found in cells treated with the drug combination, whereas individual treatments had 
minimal effects on Txnip and Ddit3 levels. YAP1 levels did not oscillate above 1 under these 
conditions but were decreased over time (Figure 13d). Thus, we report that that the UPR targets 
Txnip and Ddit3 exhibit a circadian-like oscillation expression pattern, though not to say extent, 
further linking UPR to the clock in our system. 
 
To validate that general ATF4 and ATF6-mediated transcription were upregulated in 
response to SAHA/JQ1 we treated KP cells expressing GFP reporters for these transcription 
factors for 24 hrs and found substantial activation of both ATF4 and ATF6-mediated transcription 
(Figure 14 and b). To demonstrate that YAP1 suppresses UPR in vivo in our system we stained 
tumor sections from allografts expressing scramble shRNA vs Rela shRNA as well as our KP, 
KPY, and SAHA/JQ1 treated KP tumors for Gadd34 expression. We found that loss of Yap1/NF-
kB upregulated Gadd34 expression in vivo (Figure 14c and d). Next, we performed IHC to 
investigate TXNIP and CHOP expression in human skeletal muscle compared to UPS and 
observed decreased nuclear staining in UPS relative to muscle tissue (Figure 14e). 
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Figure 13: SAHA/JQ1 treatment promotes UPR target oscillation 
A) qRT-PCR of KP cells treated with 2 μM SAHA and/or 0.5 μM JQ1 for 0-120 hrs.  
B) qRT-PCR of HT-1080 cells treated with 2 μM SAHA and/or 0.5 μM JQ1. 
C) Summary graphs of qRT-PCR for TXNIP and DDIT3 treated as in A and B with the 
addition of 0-24 hr time points. 
D) qRT-PCR of KP (left) and HT-1080 cells (right) treated with 2 μM SAHA/ 0.5 μM JQ1 for 
0-120 hrs. 
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Figure 14: SAHA/JQ1 treatment induces the PERK and ATF6 arms of the UPR 
A) ATF4-GFP reporter assay in KP cells treated as in A for 24 hrs. Scale bar= 50 μm. 
B) ATF6-GFP reporter assay in KP cells treated as in A for 24 hrs. Scale bar= 50 μm.  
C) Representative images of IHC from murine tumor sections from allograft experiments 
(shSCR, shRelA) and GEMMs (KP, KPY, and KP tumors treated with SAHA/JQ1 once 
daily with 25mg/kg SAHA and twice daily with 25mg/kg JQ1). Tumors harvested after 20 
days of treatment. Scale bar= 20 μm.  
D) G) Quantification of Gadd34 expression from F. n=3 mice per group, 12 images per 
tumor sample. Error bars represent SD.  
E) Representative IHC of normal TXNIP and CHOP expression in human skeletal muscle 
and UPS tissues. Scale bar= 50 μm. 
*Jessica M. Posimo, Gabrielle E. Ciotti, and Susan Chor helped by performing experiments and analyzing data. 
 
  
    56   
Pharmacological and genetic inhibition of YAP1 alters sarcoma cell metabolism 
The primary known function of circadian circuitry is to regulate cellular metabolism (Bass 
& Takahashi 2010; Altman et al. 2015). Cancer cell metabolism is highly deregulated and favors 
the rapid, yet inefficient, energy production associated with glycolysis (Altman et al. 2015). We 
hypothesized that activation of clock gene expression would alter the metabolic phenotype in 
sarcoma cells. Therefore, we evaluated key metabolic genes in our microarray analysis of DMSO 
and SAHA/JQ1 treated KP cells and observed differential gene expression of cancer metabolism 
hallmarks, such as Fatty acid synthase (Fasn) (Figure 15a). We also evaluated expression of the 
hallmarks of normal metabolism in differentiated cells and tissues, Cpt1a and Cpt1b. CPT1A and 
CPT1B are associated with b-oxidation of fatty acids, a slower but more efficient metabolic 
process (Carracedo et al. 2013). CPT1B is the isoform generally associated with metabolism of 
differentiated muscle, whereas CPT1A can induce autophagy (Niso-Santano et al. 2015). We 
found that Fasn was downregulated dramatically along with Yap1, while Cpt1a and Cpt1b and the 
muscle differentiation factor Mef2c were elevated in SAHA/JQ1 treated cells. Interestingly, Cpt1a 
was increased substantially more than Cpt1b. We then evaluated publicly available datasets for 
expression of CPT1A, CPT1B, and FASN in skeletal muscle, additional normal human tissues, 
fibrosarcomas, and UPS. CPT1A levels in most of these tumors are modestly elevated or 
unchanged relative to normal tissues (Figure 15b) whereas muscle-specific CPT1B is lost and 
FASN is increased uniformly in fibrosarcomas and UPS. (Figure 15c and d). We observed that 
SAHA/JQ1 treatment suppressed Fasn expression and upregulated Cpt1a by qRT-PCR (Figure 
15e and f) and Western blot of murine and human UPS cells (Figure 15g and h). These data 
suggest that Cpt1a induction may compensate for the lack of substantial Cpt1b increase during 
SAHA/JQ1-mediated differentiation of KP cells (Figure 15a). Consistent with our prediction that 
metabolic changes are linked to differentiation, Fasn is substantially decreased in our C2C12 
differentiation model by day 6 (Figure 15i). To determine if these metabolic alterations were 
directly linked to the Yap1/NF-kB  axis we silenced Yap1 (Figure 15j, left) or Rela (Figure 15j, 
right) in KP cells with specific shRNA. Inhibition of Yap1 or Rela increased Cpt1a and Mef2c 
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mRNA expression (Figure 15j), suggesting that YAP1 is necessary to suppress differentiation, 
potentially via β-oxidation of fatty acids or autophagy mediated by the CPT1 enzymes. Next, we 
performed a rescue experiment to determine if YAP1-mediated suppression of the circadian clock 
controls metabolism and differentiation. We treated KP cells with SAHA/JQ1 and Per1 shRNA 
alone or in combination. We observed an increase in Cpt1a and Mef2c and loss of Yap1 under 
SAHA/JQ1 treatment as predicted (Figure 15k). Moreover, loss of Per1 prevented SAHA/JQ1-
mediated induction of Cpt1a and Mef2c. We observed the same trends in KP cells treated with 
SAHA/JQ1 and Arntl-specific shRNA (Figure 15l). Interestingly, Fasn gene expression appears 
to be YAP1-independent. Our shRNA-mediated YAP1 inhibition shows no reduction of Fasn (not 
shown) and loss of clock activity does not restore Fasn levels. These observations suggest that 
YAP1 signaling may coordinate with at least one other pathway to modulate metabolism. To 
further characterize the metabolic status of control vs. SAHA/JQ1-treated KP cells we performed 
GSEA of the DMSO vs. SAHA/JQ1 microarray. We observed that “MTORC1 signaling” is 
downregulated in treated cells (Figure 15m), which is consistent with the observations of several 
other groups who reported that YAP1 regulates this pathway (Hu et al. 2017; Park et al. 2016). 
MTORC1 promotes cell growth by activating biosynthesis and suppressing autophagy (Jung et al. 
2010; Laplante & Sabatini 2012). The GSEA also revealed that “Glycolysis” is significantly 
downregulated in SAHA/JQ1 treated cells, while “lipid catabolic processes” are upregulated. 
Together, these data show that the Yap1/NF-kB axis favors the expression of cancer associated 
metabolism markers and that inhibition of this pathway promotes expression of muscle markers 
and muscle-associated metabolism. 
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Figure 15: YAP1 loss alters sarcoma cell metabolism and initiates differentiation 
A) Gene expression analysis of microarray performed on KP cells treated with 2 μM SAHA/ 
0.5 μM JQ1 for 48 hrs.  
B) Oncomine gene expression analysis of CPT1A in human tissues.  
C) Oncomine gene expression analysis of CPT1B in human tissues.  
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D) Oncomine gene expression analysis of FASN in human tissues.  
E) qRT-PCR validation of Fasn in KP cells treated as in A.  
F) qRT-PCR validation of Cpt1a in KP cells treated as in A.  
G) Western blot of KP cells treated as in A.  
H) Western blot of STS-109 cells treated as in A.  
I) Western blot of proliferating (Day 0, D0) and differentiating (D1-D6) C2C12 myoblasts.  
J) qRT-PCR of KP cells expressing (right) Yap1 shRNAs and (left) Rela shRNAs.  
K) qRT-PCR rescue assay of KP cells expressing Per1 shRNA and treated as in A. 
L) qRT-PCR of KP cells expressing Arntl shRNA and treated as in A. 
M) GSEA analysis of microarray from KP cells treated as in A using the Broad Institute 
“hallmark” gene sets for “MTORC1 signaling”, “Glycolysis”, and “Lipid catabolic process”. 
Error bars represent SD.  
*Shuai Ye, Gabrielle E. Ciotti, Susan Chor, Gloria Marino, and Shaun Egolf helped by performing experiments and 
analyzing data. 
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YAP1, but not NF-kB, suppresses autophagy in UPS cells 
In addition to its established role in fatty acid oxidation, CPT1A is also associated with 
upregulation of autophagy (Niso-Santano et al. 2015). To determine which of these two 
processes occurs during SAHA/JQ1-mediated differentiation we performed GCMS evaluating 
oxidation of 75 µM [U-13C16]palmitic acid and 75 µM [U-13C18]oleic acid via enrichment of TCA 
cycle intermediates and observed a modest but reproducible decrease in β-oxidation of fatty 
acids in SAHA/JQ1 treated cells (Figure 16a). These data suggest that β-oxidation changes do 
not correlate with the differentiation phenotype induced by epigenetic modulation. Therefore, we 
investigated the ability of this drug combination to induce autophagy. Autophagy is directly 
associated with muscle function and maintenance of muscle mass (Fortini et al. 2016; Masiero et 
al. 2009). The DMSO vs. SAHA/JQ1 microarray revealed that treatment upregulates many genes 
associated with autophagy including Atg13 and Atg14, which are specifically linked to muscle 
development and function (Figure 16b). Importantly, we also saw dramatic induction of the 
autophagy marker LC3 in KP cells treated with SAHA/JQ1 and Bafilomycin (BAF) (Figure 16c, 
top). BAF interrupts autophagic flux by inhibiting maturation of autophagic vacuoles during the 
late stages of autophagy, forcing accumulation of the autophagosome-associated LC3-II. 
Consistently, shRNA-mediated depletion of Yap1 also enhanced LC3A/B expression in BAF 
treated cells, relative to control shRNA (Figure 16c, bottom). Using Yap1 shRNA we also 
screened KP cells to determine which autophagy related genes are Yap1-dependent and 
observed that Yap1 loss upregulates Atg13 and Atg14 mRNA expression (Figure 16d). 
Additionally, we observed increased Atg14 mRNA expression in tumors from KPY tumors relative 
to KP (Figure 16e). Most significantly, we observed loss of p62 and dramatic accumulation of 
LC3B in vivo in KPY (Yap1-deleted) tumors and KP tumors treated with SAHA/JQ1 relative to 
control KP tumors (Figure 16f-h). SAHA/JQ1 treatment was initiated when KP tumors reached 
100mm3 according to the schedule found in Figure 16i. Together these findings clearly link YAP1 
to autophagy regulation in UPS. Lastly, we investigated whether YAP1-mediated suppression of 
autophagy was NF-kB- and clock-dependent. Inhibition of NF-kB using Rela shRNA had no effect 
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on LC3A/B accumulation (Figure 16j) or Atg13 and Atg14 levels (Figure 16k). Moreover, we 
expressed Per1 shRNA in SAHA/JQ1 treated KP cells and found that clock modulation has no 
effect on Atg13 and Atg14 induction (Figure 16l) and that Atg13 does not oscillate at all during 
C2C12 differentiation, whereas Atg14 oscillates extremely modestly (Figure 16m). These data 
indicate that ATG13 and ATG14, and perhaps autophagy in general is not required for muscle 
differentiation but is required for muscle maintenance and function as demonstrated by other 
groups (Masiero et al. 2009; Sandri et al. 2013).  Lastly, we investigated potential crosstalk 
between the UPR and autophagy in this context. We treated KP cells expressing Txnip/Ddit3 
specific shRNAs with SAHA/JQ1 and BAF. Inhibition of Txnip and Ddit3 had no effect on 
SAHA/JQ1-mediated autophagy (Figure 16n). We conclude from these observations that YAP1 
suppresses autophagy. These data reveal that SAHA/JQ1 induces autophagy via YAP1 inhibition 
in sarcoma cells. Moreover, my data shows that induction of autophagy in sarcoma cells is 
independent of NF-kB signaling indicating that YAP1 controls multiple key aspects of cell survival 
and proliferation in muscle-derived sarcoma cells (Figure 17a and b). 
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Figure 16: YAP1 suppresses autophagy in sarcoma cells independent of NF-kB 
A) GC/MS of KP cells treated with 2 μM SAHA/ 0.5 μM JQ1 for 48 hrs.  
B) Gene expression analysis of microarray described in A.  
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C) (top) Western blot of KP cells treated as in A with the addition of BAF during the last 6 hr 
of treatment. (bottom) Western blot of YAP1 shRNA expressing cells treated with BAF as 
in the top panel.  
D) qRT-PCR of Atg13 and Atg14 in KP cells expressing Yap1 shRNA.  
E) qRT-PCR of KP and KPY tumors.  
F) Representative images of IHC from murine tumor sections from KP, KPY, and KP tumors 
treated with SAHA/JQ1 once daily with 25mg/kg SAHA and twice daily with 25mg/kg 
JQ1. Tumors harvested after 20 days of treatment. Scale bar= 20 μm.  
G) Quantification of p62 expression from F. n=3 mice per group, 12 images per tumor 
sample.  
H) Quantification of LC3B expression from F n=3 mice per group, 12 images per tumor 
sample. 
I) Drug scheduling for KP GEMM treatment beginning when tumors measure 100mm3. 
J) Western blot of KP cells expressing Scr or Rela shRNAs treated as in A with the addition 
of BAF during the last 6 hrs of treatment. 
K) qRT-PCR of KP cells expressing Rela shRNA. 
L) J) qRT-PCR rescue assay of KP cells expressing Per1 shRNA and treated with 2 μM 
SAHA/ 0.5 μM JQ1 for 48 hrs. 
M) qRT-PCR for Atg13 and Atg14 genes in proliferating (Day 0, D0) and differentiating (D1-
D6) C2C12 myoblasts.  
N) Western blot of KP cells expressing both Txnip and Ddit3 shRNAs and treated as in B 
with the addition of BAF during the last 6 hrs of treatment. Txnip/Ddit3 denotes that KP 
cells were first transfected with Txnip shRNA followed by Ddit3 shRNA, and inverse for 
Ddit3/Txnip lane. Error bars represent SD. 
*Shuai Ye, Gabrielle E. Ciotti, Susan Chor, Ying Liu, Gloria Marino, and Shaun Egolf helped by performing 
experiments and analyzing data. 
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Figure 17: Model of YAP1/NF-kB-mediated clock control of UPR and NF-kB-independent 
control of autophagy 
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Discussion 
Though well studied in epithelial tumors, the specific downstream effectors of YAP1 in 
sarcomas are still being elucidated. Characterization of these effectors is necessary for the 
development of effective biomarkers and targeted therapies to treat YAP1-dependent tumors 
including UPS. Previously, we demonstrated that YAP1 promotes proliferation via persistent 
elevated NF-kB signaling (Ye et al. 2018). The goal of this study was to elucidate the 
mechanisms by which YAP1 and NF-kB impact muscle de-differentiation and promote 
tumorigenesis. My work shows that YAP1-mediated NF-kB signaling represses UPR and 
circadian clock activity, both of which are required for muscle differentiation (Andrews et al. 2010; 
Xiong et al. 2017).  We also show that YAP1 inhibits autophagy in an NF-kB-independent 
manner. 
 
To our knowledge, this work provides the first direct link between the Hippo pathway and 
circadian clock activity. Using our autochthonous mouse models, I demonstrated that Yap1-
mediated NF-kB activity disrupts normal circadian oscillation by suppressing Per1, Per2 and Cry2 
levels. Consistent with this observation, PER1, PER2, and CRY2 are downregulated in human 
UPS (Ye et al. 2018). We also demonstrate that genetic or pharmacological inhibition of YAP1 
enhances circadian clock activity and the oscillation of key targets including Txnip, which is a 
major effector of the UPR (Oslowski et al. 2012; Y. Ma et al. 2002).  
 
One critical purpose of the UPR and circadian clock is regulation of metabolic processes 
(Bohnert et al. 2018). We found that Yap1-mediated suppression of the UPR and clock support a 
shift in metabolism toward cancer cell-associated glycolysis and hyper-proliferation. Reactivation 
of the UPR and clock via SAHA/JQ1 correlate with decreased glycolysis while enhancing 
autophagy and lipid catabolism, thus promoting skeletal muscle differentiation. 
Our work sheds light on several on-going areas of cancer research. First, our observation 
that the clock and the UPR are both activated in differentiating myoblasts, as well as SAHA/JQ1-
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treated sarcoma cells, indicates that the relationship between these two processes is context-
dependent. Whereas in some tissues the UPR antagonizes clock gene expression (Bu et al. 
2018), in skeletal muscle and muscle-derived tumors both pathways are critical for differentiation 
and can be simultaneously upregulated (Andrews et al. 2010; Xiong et al. 2017; Bohnert et al. 
2016). This idea is consistent with several studies showing that UPR is necessary for muscle 
regeneration and maintenance of muscle mass (Bohnert et al. 2018; Xiong et al. 2017; Bohnert et 
al. 2016; Nakanishi et al. 2007).  
 
Similarly, clock function is necessary for muscle generation and differentiation. In fact, 
MyoD, is a direct transcriptional target of the molecular clock (Andrews et al. 2010; X. Zhang et 
al. 2012; Lefta et al. 2011). Clock deficient mice suffer from muscle weakness, cachexia, and 
disrupted metabolism (Bohnert et al. 2016). However, little is known about upstream signaling 
inputs that control clock gene expression and function. Now we appreciate that aberrant Yap1 
stabilization impacts these processes in muscle-derived sarcomas and potentially other contexts 
as well. In future studies, we will determine how Yap1 suppresses clock, UPR gene expression, 
and autophagy. Yap1 is generally considered a transcriptional activator. As such, our findings 
highlight novel roles for Yap1 in suppressing transcription. The targets repressed by Yap1 are 
particularly intriguing to us. Whereas, we might predict that Yap1 would inhibit expression of pro-
apoptotic genes our work suggests that Yap1, via NF-kB, also represses pro-differentiation 
genes. This hypothesis is supported by data indicating that Yap1 inhibits muscle differentiation in 
C2C12 myoblasts (Watt et al. 2010).  
 
Lastly, we sought to determine the utility of epigenetic modulation in the treatment of 
muscle-derived sarcomas. We previously reported their impressive efficacy in the KP GEMM (Ye 
et al. 2018). Here we validate our earlier finding that this strategy inhibits proliferation and 
enhances differentiation. We have identified key differentiation targets including clock, UPR, and 
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autophagy genes as biomarkers of SAHA/JQ1 efficacy and suggest that this therapeutic strategy 
and these markers may offer clinical benefit to some sarcoma patients. 
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Chapter 4: Conclusion 
 
Our results identify a network of signaling mechanisms regulated by Hippo signaling 
pathway inactivation and YAP1 stabilization to promote sarcomagenesis. Although YAP1 has 
been extensively studied in epithelial tumors, the downstream effectors of YAP1 in sarcoma 
remain to be elucidated. Thus, characterization of these effectors is of high importance for the 
development of targeted therapies and as effective biomarkers in patients with UPS and other 
YAP1-dependent tumors. We have previously demonstrated that YAP1 hyperactivation and 
stabilization promotes persistent canonical NF-kB signaling. Activation of the YAP1-NF-kB axis 
promotes UPS proliferation and sarcomagenesis, and antagonizes muscle differentiation (Ye et 
al. 2018). Thus, it was our goal to elucidate the downstream mechanisms by which the YAP1-NF-
kB axis promotes sarcomagenesis and inhibits muscle differentiation.  
 
My work demonstrates that inactivation of Hippo signaling pathway, resulting in YAP1 
stabilization, inhibits muscle differentiation and promotes proliferation and sarcomagenesis in 
UPS by repressing circadian clock activity, the UPR, and autophagy. Consistent with the 
observation that PER1, PER2, and CRY2 are downregulated in human UPS, I show that the 
YAP1-NF-kB axis suppresses Per1, Per2, and Cry2 levels in vivo and that genetic and 
pharmacological inhibition of YAP1 reactivates circadian clock activity in vitro. Moreover, genetic 
and pharmacological ablation of YAP1 enhanced oscillation of the circadian clock genes and 
Txnip,, a major effector of the UPR (Bohnert et al. 2016; Nakanishi et al. 2007). Activation of the 
UPR and circadian clock become activated in differentiating myoblasts and SAHA/JQ1 treated 
sarcoma cells further demonstrates that the relationship between these two processes is context 
dependent. In summary, these findings shed light on multiple on-going areas of cancer research.  
Though in some cancers and tissues the UPR has been shown to antagonize clock gene 
expression, in skeletal muscle and muscle-derived tumors activation of the UPR and circadian 
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clock are important for differentiation and survival during differentiation (Bu et al. 2018). In UPS 
we found that YAP1 suppresses the UPR and circadian clock, thus both pathways can be 
simultaneously upregulated (Andrews et al. 2010; Xiong et al. 2017; Bohnert et al. 2016). This is 
consistent with the idea that the UPR is necessary for skeletal muscle regeneration and muscle 
mass maintenance (Bohnert et al. 2018; Xiong et al. 2017; Bohnert et al. 2016). Moreover, the 
main muscle specific transcription factor, MyoD, is a direct transcriptional target of the circadian 
clock (Andrews et al. 2010; X. Zhang et al. 2012; Lefta et al. 2011). Additionally, ER stress and 
the UPR target protein CHOP and the ATF6 arm of the UPR are also known to play a role in 
muscle differentiation and myofiber formation (Alter & Bengal 2011; Nakanishi et al. 2005; 
Nakanishi et al. 2007). My work suggests that YAP1, via NF-kB, represses the UPR, circadian 
clock, and pro-differentiation genes. This hypothesis is supported by data indicating that YAP1 
inhibits muscle differentiation in C2C12 myoblasts (Watt et al. 2010). 
 
The circadian clock and UPR are also known to regulate metabolic processes (Bohnert et 
al., 2018). We found that inhibition of both the UPR and circadian clock supports a shift in 
metabolism toward cancer cell-associated glycolysis and hyperproliferation. In contrast, 
reactivation of the UPR and circadian clock promoted a shift from cancer cell-associated 
glycolysis and hyperproliferation to lipid catabolism and enhanced autophagy. Whereas 
autophagy is necessary for skeletal muscle differentiation and survival during differentiation, clock 
deficient mice suffer from muscle weakness, cachexia and disrupted metabolism (Andrews et al. 
2010; Bohnert et al. 2016). These observations further support our findings that deregulation of 
circadian clock, UPR, and autophagy gene expression and activity inhibit skeletal muscle 
differentiation and promotes proliferation and growth. Furthermore, my work demonstrates that 
YAP1-mediated inhibition of autophagy is independent of NF-kB signaling. In terms of the 
upstream signals that control the clock, little is known. 
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Finally, we sought to determine the effects of epigenetic drugs as potential treatments for 
muscle-derived sarcomas. We validated the use of SAHA/JQ1 as a treatment modality in our in 
vivo and in vitro system. Similar to genetic ablation of YAP1, treatment with SAHA/JQ1 induces 
differentiation and inhibits proliferation. Additionally, SAHA/JQ1-mediated activation of the UPR 
enhances autophagy. My work identified key UPR, circadian clock and autophagy differentiation 
targets that could function as biomarkers of SAHA/JQ1 efficacy and could offer clinical benefits to 
some sarcoma patients.  
 
Future Directions 
YAP1 as a transcriptional repressor 
YAP1 is a known potent transcriptional regulator. Our data highlight novel roles for Yap1 
in suppressing transcription. In future studies, we will determine the mechanism by which Yap1 
suppresses circadian clock, UPR, and autophagy gene expression and activity. As discussed 
previously, YAP1 must translocate into the nucleus and bind the Tea Domain Family of 
transcription factors (TEAD) proteins to promote a pro-proliferation transcriptional program (Ye et 
al. 2018; Liu-Chittenden et al. 2012; Zhao et al. 2007; Barron & Kagey 2014). We have previously 
shown that YAP1 predominantly interacts with TEAD1 and TEAD4 in sarcoma cells (Eisinger-
Mathason et al. 2015). My work, however, has shed light on the paradigm shifting concept, 
proposed by us, that YAP1 can potentially function as a transcriptional repressor of UPR, 
circadian clock, and autophagy genes in order to impair muscle differentiation.  
 
To determine that YAP1 is directly inhibiting transcription of UPR, circadian clock, and 
autophagy genes we will perform ChIP-seq and RNA-seq. We will first validate if TEAD binding 
sites exist proximal to the various target genes affected by YAP1 and described in Chapter 3. I 
expect the YAP1-TEAD complex to bind the M-CAT motif and inhibit transcription of target genes. 
Moreover, we will determine the epigenetic landscape of the target genes, which I expect to be in 
inaccessible to factors that promote transcription. Alternatively, it is possible that YAP1-TEAD 
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promotes transcription of genes or non-coding RNAs that repress transcription of UPR, circadian 
clock, and autophagy genes. 
 
Mouse Models and Pharmacological Approaches 
To further test the contribution of NF-kB signaling to sarcomagenesis in vivo, we 
developed the KPR mouse model. We observed that KPR mice do not develop tumors. 
Moreover, we validated this finding by performing genetic knockdown of RelA in our in vitro 
system and reduced sarcomagenesis as well as increased circadian clock gene transcription and 
activity, and UPR gene transcription. Thus, NF-kB ablation led to reduced sarcoma 
growth/proliferation. To determine if constitutive activation of NF-kB rescues YAP1 deficient 
proliferation, we will breed KPY mice (YAP deficient) with LSL-Ikk2CA to generate KPYICA mice. I 
expect that KPYICA tumor size will be comparable to KP tumors, indicating that constitutive NF-kB 
activity rescues the loss of Yap1 in this context. Furthermore, we will treat KPYICA mice with 
SAHA/JQ1 to determine if we can extend animal survival, which would further support a model in 
which SAHA/JQ1 inhibits NF-kB activity and promote a potential shift from a pro-proliferation 
transcriptional program to a differentiation transcriptional program. Alternatively, our KP versus 
KPY microarray analysis revealed a list of NF-kB targets that includes Phlda1, Bcl3, Areg, and 
Egr1. If the current shortlist of NF-κB targets are not individually necessary for UPS proliferation, 
we will explore combination deletions as well additional targets identified by gene expression 
analysis in SAHA/JQ1 treated cells and YAP1 deficient cells. Then we will determine the whether 
these targets are critical for differentiation rather than proliferation, using a C2C12 model of 
undifferentiated myoblasts. 
 
My work shows that YAP1-NF-kB axis inhibits UPR and circadian clock gene expression 
and activity. Moreover, I show that YAP1 inhibits autophagy in an NF-kB independent manner. 
Thus, it is of great interest for us to test the contribution of the UPR, circadian clock, and 
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autophagy in UPS initiation, progression and survival. To determine the contributions of the 
circadian clock in UPS, we will cross KPY mice with BMAL deficient mice to develop KPYB. To 
test the contribution of the UPR, we will cross KPY mice with TXNIP and CHOP to develop KPYT 
and KPYC mice. I expect KPYB, KPYT and KPYC tumors to be larger in size than KPY tumors 
but smaller than KP tumors, as our findings suggest that circadian clock and UPR activity 
promotes muscle differentiation and inhibits UPS proliferation. Last, to determine the contribution 
of autophagy in UPS we will cross KPY mice with FIP200 conditional knockout mice to produce 
KPYF. FIP200 is a component of a molecular complex that includes ATG13, required for 
autophagosome formation, and known to promote mammary tumorigenesis ((Hara & Mizushima 
2009; Wei et al. 2011). I expect that KPYF tumor size will be smaller than KPY tumors, indicating 
that autophagy is required for UPS survival. Alternatively, we can treat KPY mice with known 
pharmacological inhibitors of the UPR and autophagy, such as 4-PBA and chloroquine, 
respectively. Alternatively, to inhibit the clock, we would follow a new approach, established in Chi 
Dang’s lab, in which stabilizing HIF with DMOG and/or increasing the acidity of media disrupts 
circadian clock oscillation (Walton et al. 2018). 
 
Future potential treatments for sarcoma 
Our data show the Hippo pathway inhibits the UPR, circadian clock and autophagy, 
which all contribute and are important for muscle differentiation. Currently there are no targeted 
therapies for soft tissue sarcoma patients (M. Zhang et al. 2014). However, we observed 
inactivation of the Hippo pathway and increased stabilization of YAP1 in UPS (Eisinger-Mathason 
et al. 2015). Thus, YAP1 drives a pro-proliferation transcriptional program that promotes 
sarcomagenesis and metastasis (Eisinger-Mathason et al. 2015). In UPS, we observed that 
YAP1 stabilization and translocation into the nucleus occurs because of epigenetic silencing of its 
inhibitor, AMOT, and Hippo pathway kinase deletion (Ye & Eisinger-Mathason 2016). Additionally, 
in human UPS tumor sections, we observed increase protein expression of the canonical NF-kB 
transcriptional factor, phosphorylated p65. We demonstrated that YAP1, in fact, promotes 
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sarcomagenesis and inhibits muscle differentiation, in part, by sustaining constitutive canonical 
NF-kB signaling (Ye et al. 2018). Moreover, we have demonstrated that KP cells are sensitive to 
the NF-kB inhibitors BAY11-7085 and CAPE (Ye et al. 2018). Thus, NF-kB inhibition offers new 
and viable therapeutic options to treat sarcoma. It is important to note that the most widely used 
NF-kB inhibitors available have specificity issues. Thus, we are currently working in collaboration 
with Dr. Anne Carpenter’s laboratory to develop our own NF-kB inhibitor. It is our goal to develop 
a specific NF-kB pharmacological inhibitor. 
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